<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><?covid-19-tdm ?><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">70658</article-id><article-id pub-id-type="doi">10.7554/eLife.70658</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-239757"><name><surname>Barton</surname><given-names>Michael I</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9263-6481</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-186946"><name><surname>MacGowan</surname><given-names>Stuart A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4233-5071</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-141919"><name><surname>Kutuzov</surname><given-names>Mikhail A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3386-4350</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-46608"><name><surname>Dushek</surname><given-names>Omer</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5847-5226</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-3241"><name><surname>Barton</surname><given-names>Geoffrey John</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9014-5355</contrib-id><email>g.j.barton@dundee.ac.uk</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-59843"><name><surname>van der Merwe</surname><given-names>P Anton</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9902-6590</contrib-id><email>anton.vandermerwe@path.ox.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution>Sir William Dunn School of Pathology, University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution>School of Life Sciences, University of Dundee</institution><addr-line><named-content content-type="city">Dundee</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Fouchier</surname><given-names>Ron AM</given-names></name><role>Reviewing Editor</role><aff><institution>Erasmus Medical Center</institution><country>Netherlands</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Van der Meer</surname><given-names>Jos W</given-names></name><role>Senior Editor</role><aff><institution>Radboud University Medical Centre</institution><country>Netherlands</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>26</day><month>08</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e70658</elocation-id><history><date date-type="received" iso-8601-date="2021-05-25"><day>25</day><month>05</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-08-20"><day>20</day><month>08</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-05-18"><day>18</day><month>05</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.05.18.444646"/></event></pub-history><permissions><copyright-statement>© 2021, Barton et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Barton et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-70658-v3.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-70658-figures-v3.pdf"/><related-article ext-link-type="doi" id="ra1" related-article-type="article-reference" xlink:href="10.7554/eLife.70657"/><abstract><p>The interaction between the SARS-CoV-2 virus Spike protein receptor binding domain (RBD) and the ACE2 cell surface protein is required for viral infection of cells. Mutations in the RBD are present in SARS-CoV-2 variants of concern that have emerged independently worldwide. For example, the B.1.1.7 lineage has a mutation (N501Y) in its Spike RBD that enhances binding to ACE2. There are also ACE2 alleles in humans with mutations in the RBD binding site. Here we perform a detailed affinity and kinetics analysis of the effect of five common RBD mutations (K417N, K417T, N501Y, E484K, and S477N) and two common ACE2 mutations (S19P and K26R) on the RBD/ACE2 interaction. We analysed the effects of individual RBD mutations and combinations found in new SARS-CoV-2 Alpha (B.1.1.7), Beta (B.1.351), and Gamma (P1) variants. Most of these mutations increased the affinity of the RBD/ACE2 interaction. The exceptions were mutations K417N/T, which decreased the affinity. Taken together with other studies, our results suggest that the N501Y and S477N mutations enhance transmission primarily by enhancing binding, the K417N/T mutations facilitate immune escape, and the E484K mutation enhances binding and immune escape.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>As the COVID-19 pandemic has progressed, new variants of the virus SARS-CoV-2 have emerged that are more infectious than the original form. The variants known as Alpha, Beta and Gamma have mutations in a protein on the virus’s surface that is vital for attaching to cells and infecting them. This protein, called Spike, carries out its role by binding to ACE2, a protein on the surface of human cells. Mutations on Spike are found on the region where it binds to ACE2.</p><p>The interaction between these two proteins appears to be important to the behaviour of SARS-CoV-2, but the impact of individual mutations in Spike is unknown. In addition, some people have different variants of ACE2 with mutations in the region that interacts with Spike, but it is not known whether this affects these people’s risk of contracting COVID-19.</p><p>To answer these questions, Barton et al. measured the precise effect of mutations in Spike and ACE2 on the strength of the interaction between the two proteins. The experiments showed that three of the five common Spike mutations in the Alpha, Beta and Gamma SARS-CoV-2 variants strengthened binding to ACE2. The two mutations that weakened binding were only found together with other mutations that strengthened binding. This meant that the Spike proteins in all three of these SARS-CoV-2 variants bind to ACE2 more strongly than the original form. The experiments also showed that two common variants of ACE2 also increased the strength of binding to Spike. Interestingly, one of these ACE2 variants reversed the effect of a specific SARS-CoV-2 mutation, suggesting that carriers would be resistant to SARS-CoV-2 variants with this mutation.</p><p>Identifying the precise effects of Spike mutations on ACE2 binding helps understand why new variants of SARS-CoV-2 spread more rapidly. This could help to identify concerning new variants before they spread widely and inform the response by health authorities. The finding that two common ACE2 variants bind more strongly to Spike suggests that people with these mutations could be more susceptible to SARS-CoV-2.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>ACE2</kwd><kwd>viral receptor</kwd><kwd>affinity</kwd><kwd>coronavirus</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>207537/Z/17/Z828</award-id><principal-award-recipient><name><surname>Kutuzov</surname><given-names>Mikhail A</given-names></name><name><surname>Dushek</surname><given-names>Omer</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/J019364/1</award-id><principal-award-recipient><name><surname>MacGowan</surname><given-names>Stuart A</given-names></name><name><surname>Barton</surname><given-names>Geoffrey John</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/R014752/1</award-id><principal-award-recipient><name><surname>MacGowan</surname><given-names>Stuart A</given-names></name><name><surname>Barton</surname><given-names>Geoffrey John</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>101651/Z/13/Z).</award-id><principal-award-recipient><name><surname>MacGowan</surname><given-names>Stuart A</given-names></name><name><surname>Barton</surname><given-names>Geoffrey John</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Common variants of the SARS-CoV-2 Spike protein and its ligand, the human ACE2 receptor, increase the binding affinity, suggesting that they could increase viral transmissibility.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Since its identification in 2019, a coronavirus able to induce a severe acute respiratory syndrome in humans, SARS-CoV-2, has resulted in arguably the most severe infectious disease pandemic in 100 years. To date, more than 135 million people have been infected, resulting in the deaths from the resulting disease, COVID-19, of more than 3 million people (<xref ref-type="bibr" rid="bib50">WHO, 2021</xref>), and measures introduced to control spread have had harmful social and economic impacts. Fortunately, effective vaccines have been developed, and a global vaccination programme is underway (<xref ref-type="bibr" rid="bib27">Mahase, 2021</xref>). New SARS-CoV-2 variants of concern are emerging that are making containment of the pandemic more difficult, perhaps by increasing transmissibility of the virus (<xref ref-type="bibr" rid="bib7">Davies et al., 2021</xref>; <xref ref-type="bibr" rid="bib18">Korber et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Volz et al., 2021b</xref>; <xref ref-type="bibr" rid="bib45">Volz et al., 2021b</xref>; <xref ref-type="bibr" rid="bib48">Washington et al., 2021</xref>) and/or its resistance to protective immunity induced by previous infection or vaccines (<xref ref-type="bibr" rid="bib6">Darby and Hiscox, 2021</xref>; <xref ref-type="bibr" rid="bib8">Dejnirattisai et al., 2021</xref>; <xref ref-type="bibr" rid="bib9">Garcia-Beltran et al., 2021</xref>; <xref ref-type="bibr" rid="bib25">Madhi et al., 2021a</xref>; <xref ref-type="bibr" rid="bib26">Madhi et al., 2021b</xref>; <xref ref-type="bibr" rid="bib27">Mahase, 2021</xref>; <xref ref-type="bibr" rid="bib45">Volz et al., 2021b</xref>; <xref ref-type="bibr" rid="bib45">Volz et al., 2021b</xref>).</p><p>The SARS-CoV-2 virus enters cells following an interaction between the Spike (S) protein on its surface with angiotensin-converting enzyme 2 (ACE2) on cell surfaces (<xref ref-type="bibr" rid="bib46">V’kovski et al., 2021</xref>). The receptor-binding domain (RBD) of the Spike protein binds the membrane-distal portion of the ACE2 protein. The S protein forms a homotrimer, which is cleaved shortly after synthesis into two fragments that remain associated non-covalently: S1, which contains the RBD, and S2, which mediates membrane fusion following the binding of Spike to ACE2 (<xref ref-type="bibr" rid="bib46">V’kovski et al., 2021</xref>). During the pandemic, mutations have appeared in the Spike protein that may increase transmissibility (<xref ref-type="bibr" rid="bib7">Davies et al., 2021</xref>; <xref ref-type="bibr" rid="bib18">Korber et al., 2020</xref>; <xref ref-type="bibr" rid="bib32">Richard et al., 2021</xref>; <xref ref-type="bibr" rid="bib45">Volz et al., 2021b</xref>; <xref ref-type="bibr" rid="bib45">Volz et al., 2021b</xref>; <xref ref-type="bibr" rid="bib48">Washington et al., 2021</xref>). One that emerged early in Europe, D614G, and quickly became dominant globally (<xref ref-type="bibr" rid="bib18">Korber et al., 2020</xref>), increases the density of intact Spike trimer on the virus surface by preventing premature dissociation of S1 from S2 following cleavage (<xref ref-type="bibr" rid="bib56">Zhang et al., 2021</xref>; <xref ref-type="bibr" rid="bib55">Zhang et al., 2020</xref>). A later mutation, N501Y, which has appeared in multiple lineages, lies within the RBD, and increases its affinity for ACE2 (<xref ref-type="bibr" rid="bib40">Starr et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Supasa et al., 2021</xref>). These findings suggest that mutations that directly or indirectly enhance Spike binding to ACE2 may increase transmissibility.</p><p>Prior infection by SARS-CoV-2 and current vaccines induce antibody responses to the Spike protein, and most neutralising antibodies appear to bind to the Spike RBD (<xref ref-type="bibr" rid="bib9">Garcia-Beltran et al., 2021</xref>; <xref ref-type="bibr" rid="bib10">Greaney et al., 2021a</xref>; <xref ref-type="bibr" rid="bib33">Rogers et al., 2020</xref>). Some variants of concern have mutations in their RBD that confer resistance to neutralising antibodies (<xref ref-type="bibr" rid="bib6">Darby and Hiscox, 2021</xref>; <xref ref-type="bibr" rid="bib8">Dejnirattisai et al., 2021</xref>; <xref ref-type="bibr" rid="bib9">Garcia-Beltran et al., 2021</xref>; <xref ref-type="bibr" rid="bib25">Madhi et al., 2021a</xref>; <xref ref-type="bibr" rid="bib26">Madhi et al., 2021b</xref>; <xref ref-type="bibr" rid="bib27">Mahase, 2021</xref>). What is less clear is the precise effect of these mutations on the affinity and kinetics of the binding of RBD to ACE2. Previous studies of the interaction between the Spike RBD and ACE2 have produced a wide range of affinity and kinetic estimates under conditions (e.g. temperature) that are not always well defined (<xref ref-type="bibr" rid="bib21">Lei et al., 2020</xref>; <xref ref-type="bibr" rid="bib38">Shang et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Supasa et al., 2021</xref>; <xref ref-type="bibr" rid="bib52">Wrapp et al., 2020</xref>; <xref ref-type="bibr" rid="bib56">Zhang et al., 2021</xref>; <xref ref-type="bibr" rid="bib55">Zhang et al., 2020</xref>). Precise information is needed to assess the extent to which RBD mutations have been selected because they enhance ACE2 binding or facilitate immune evasion.</p><p>In this study, we undertook a detailed affinity and kinetic analysis of the interaction between Spike RBD and ACE2 at a physiological temperature (37°C), taking care to avoid common pitfalls. We used this optimised approach to analyse the effect of important common mutations identified in variants of RBD and ACE2. Both mutations of ACE2 (S19P, K26R) and most of the mutations of RBD (N501Y, E484K, and S477N) enhanced the interaction, with one RBD mutation (N501Y) increasing the affinity by ~10-fold. Increased binding was the result of decreases in dissociation rate constants (N501Y, S477N) and/or increases in association rate constants (N501Y, E484K). Although the K417N/T mutations found in the South African (B.1.351) and Brazilian (P.1) variants both decreased the affinity, the affinity-enhancing N501Y and E484K mutations that are also present in both variants confer a net ~4-fold increase in the affinity of their RBDs for ACE2.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Selection of variants</title><p>The focus of this study was to analyse common and therefore important variants of RBD and ACE2. Henceforth, we will refer to the common ACE2 allele and RBD of the original SARS-CoV-2 strain sequenced in Wuhan as wild type (WT). We chose mutations of RBD within the ACE2 binding site that have appeared independently in multiple SARS-CoV-2 lineages/clades (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib14">Hodcroft, 2021</xref>; <xref ref-type="bibr" rid="bib31">Rambaut et al., 2020</xref>), suggesting that they confer a selective advantage, rather than emerged by chance, such as through a founder effect. The N501Y mutation has appeared in the Alpha (B.1.1.7; 20I/501Y.V1), Beta (B.1.351; 20 H/501Y.V2), and Gamma (P.1; 20 J/501Y.V3) variants, which were first identified in the UK, South Africa, and Brazil, respectively. The E484K mutation is present in the Beta and Gamma variants and has appeared independently in many other lineages, including Zeta (P.2; 20B/S.484K), B.1.1.318, Eta (B.1.525; 20A/S:484 K), and Iota (B.1.526; 20 C/S.484K). E484K has also appeared in VOC-202102–02, a subset of the Alpha variant identified in the UK (<xref ref-type="bibr" rid="bib36">SARS-CoV-2 Variants of concern and variants under investigation - GOV.UK, 2021</xref>). The S477N mutation became dominant for periods in Australia (clade 20 F) and parts of Europe (20A.EU2) and then appeared in New York in the Iota or B.1.526 lineage (<xref ref-type="bibr" rid="bib57">Zhou et al., 2021a</xref>). Mutations of K417 have appeared independently in the Beta and Gamma variants. Interestingly, N501Y, E484K, and S477N were the main mutations that appeared following random RBD mutagenesis and in vitro selection of mutants with enhanced ACE2 binding (<xref ref-type="bibr" rid="bib54">Zahradník et al., 2021</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Spike RBD and ACE2 variants analysed in this study.</title><p>(<bold>A</bold>) Phylogenetic tree illustrating the clades containing the RBD mutations investigated in this study. Constructed using TreeTime (<xref ref-type="bibr" rid="bib35">Sagulenko et al., 2018</xref>) from the Nextstrain Global (<xref ref-type="bibr" rid="bib12">Hadfield et al., 2018</xref>) sample of SARS-CoV-2 sequences from the GISAID database (<xref ref-type="bibr" rid="bib39">Shu and McCauley, 2017</xref>) (accessed 15 April 2021, N = 4017). (<bold>B</bold>) Alignment illustrating the Spike residues that differ between SARS-CoV-2 variants, with the RBD mutants boxed. The variants are labelled with their clade designation from Nextstrain (<xref ref-type="bibr" rid="bib12">Hadfield et al., 2018</xref>) and/or PANGO lineage (<xref ref-type="bibr" rid="bib31">Rambaut et al., 2020</xref>), where relevant. The RBD mutations were collated from CoVariants (<xref ref-type="bibr" rid="bib14">Hodcroft, 2021</xref>) and Nextstrain. (<bold>C</bold>) The structure of human ACE2 (green) in complex with SARS-CoV-2 Spike RBD (cyan). The area enclosed by the box is shown enlarged on the right, with the residues mutated in this study labelled. Drawn using UCSF Chimera (<xref ref-type="bibr" rid="bib30">Pettersen et al., 2004</xref>) using coordinates from PDB 6m0j (<xref ref-type="bibr" rid="bib20">Lan et al., 2020</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70658-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Emergence of the same RBD mutations in multiple SAR2-CoV-2 clades.</title><p>The figure highlights the SARS-CoV-2 clades containing RBD mutations investigated in this study. The phylogenetic trees were constructed as in <xref ref-type="fig" rid="fig1">Figure 1A</xref> from SARS-CoV-2 sequences accessed on 22 April 2021 (N = 3914). (<bold>A</bold>) N501Y has emerged independently in the three clades 501Y.V1, 501Y.V2, and 501Y.V3. Mutation to T at this position has also occurred frequently. (<bold>B</bold>) E484K has also been observed independently of its main progenitor clades 501Y.V2 and 501Y.V3. E484Q and E484G have also been observed. (<bold>C</bold>) S477N has been observed beyond clades 20 F and 20A.EU2. Mutations to I and R have also been occasionally observed at this position. (<bold>D</bold>) Mutations of K417 to N and T have been observed almost exclusively in the 20 H.501Y.V2 and 20 J.501Y.V3 clades.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70658-fig1-figsupp1-v3.tif"/></fig></fig-group><p>We selected for analysis the two most common mutations of ACE2 within the RBD binding site, K26R and S19P (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). They are present in 0.4% and 0.03%, respectively, of all samples in the gnomAD database (<xref ref-type="bibr" rid="bib17">Karczewski et al., 2020</xref>), while other ACE2 mutations in the RBD binding site are much less frequent (&lt;0.004%) (<xref ref-type="bibr" rid="bib24">MacGowan et al., 2021</xref>). K26R is observed in all the major gnomAD populations but is most common in Ashkenazi Jews (1%) and (non-Finnish) north-western Europeans (0.6%). It is less common in Africans/African-Americans and South Asians (0.1%) and rare in Finnish (0.05%) and East-Asian (0.001%) populations. The S19P mutant is almost exclusively found in Africans/African-Americans (0.3%).</p></sec><sec id="s2-2"><title>Measurement of affinity and kinetics</title><p>To measure the effects of these mutations on the affinity and kinetics of the RBD/ACE2 interaction, we used surface plasmon resonance (SPR), which allows very accurate measurements, provided that common pitfalls are avoided, particularly protein aggregation, mass-transport limitations, and rebinding (<xref ref-type="bibr" rid="bib43">van der Merwe and Barclay, 1996</xref>; <xref ref-type="bibr" rid="bib28">Myszka, 1997</xref>). Monomeric, soluble forms of the ectodomain of ACE2 and the Spike RBD were expressed in human cells, to retain native glycosylation, and purified (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). ACE2 was captured onto the sensor surface via a carboxy-terminal biotin and RBD injected over ACE2 at different concentrations (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Excellent fits of 1:1 Langmuir binding model to the data yielded an association rate constant (k<sub>on</sub>) of 0.9 ± 0.05 μM<sup>–1</sup>s<sup>–1</sup> and a dissociation rate constant (k<sub>off</sub>) of 0.067 ± 0.0011 s<sup>–1</sup> (mean ± SD, n = 6, <xref ref-type="table" rid="table1">Table 1</xref>). These rate constants are up to 25- fold faster than previously reported for the same interaction (<xref ref-type="bibr" rid="bib21">Lei et al., 2020</xref>; <xref ref-type="bibr" rid="bib38">Shang et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Supasa et al., 2021</xref>; <xref ref-type="bibr" rid="bib52">Wrapp et al., 2020</xref>; <xref ref-type="bibr" rid="bib56">Zhang et al., 2021</xref>). However, previous experiments were conducted at unphysiologically low temperatures (i.e. below 37°C) and under conditions in which mass-transport limitations and rebinding are highly likely (see Discussion). These factors, and the presence of protein aggregates (<xref ref-type="bibr" rid="bib43">van der Merwe and Barclay, 1996</xref>), would all lower the measured rate constants. In contrast, our measurements were conducted at 37°C and under conditions in which mass-transfer limitation and rebinding were excluded. The latter is demonstrated by the fact that measured k<sub>on</sub> and k<sub>off</sub> rates approached maximal values at the low level of ACE2 immobilisation (~50 RU) used in our experiments (<xref ref-type="fig" rid="fig2">Figure 2B,C</xref>; <xref ref-type="bibr" rid="bib8">Dejnirattisai et al., 2021</xref>). The excellent fit of the 1:1 binding model to our data excludes an effect of protein aggregates, which yield complex kinetics. The calculated dissociation constant (K<sub>D</sub>) was 74 ± 4 nM (mean ± SD, n = 6, <xref ref-type="table" rid="table1">Table 1</xref>). We also measured K<sub>D</sub> by equilibrium binding (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), which avoids any artefacts induced by mass transfer limitations and rebinding. This K<sub>D</sub> was very similar to the value calculated from kinetic data (63 ± 7.7 nM [mean ± SD, n = 24, <xref ref-type="table" rid="table1">Table 1</xref>]), and did not vary with immobilisation level (<xref ref-type="fig" rid="fig2">Figure 2E</xref>), further validating our kinetic measurements. These affinity values are within the wide range reported in previous studies, which varied from K<sub>D</sub> 6–133 nM (<xref ref-type="bibr" rid="bib19">Laffeber et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">Lei et al., 2020</xref>; <xref ref-type="bibr" rid="bib23">Liu et al., 2021</xref>; <xref ref-type="bibr" rid="bib38">Shang et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Supasa et al., 2021</xref>; <xref ref-type="bibr" rid="bib52">Wrapp et al., 2020</xref>; <xref ref-type="bibr" rid="bib56">Zhang et al., 2021</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>SPR analysis.</title><p>(<bold>A</bold>) Overlay of traces showing association and dissociation when WT RBD is injected for 30 s at the indicated concentration over immobilised WT ACE2. The right panel shows an expanded view of the dissociation phase. The blue lines show the fits used for determining the k<sub>on</sub> and k<sub>off</sub>. The k<sub>on</sub> was determined as described in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>. The k<sub>off</sub> (<bold>B</bold>) and k<sub>on</sub> (<bold>C</bold>) values measured at different levels of immobilised ACE2 are shown. (<bold>D</bold>) The equilibrium K<sub>D</sub> was determined by plotting the binding at equilibrium against [RBD] injected. Data from experiment shown in (<bold>A</bold>). (<bold>E</bold>) The equilibrium K<sub>D</sub> measured at different levels of immobilised ACE2 are shown.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70658-fig2-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70658-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Protein purification.</title><p>Size-exclusion chromatography traces of the indicated ACE2 and RBD proteins and reducing SDS–PAGE of the indicated peak fractions. UK2 refers to the VOC-202102–02 variants. In preparations of RBD, unidentified ~60 kDa contaminants were present at various levels, but always &lt;5% by densitometry.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70658-fig2-figsupp1-v3.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Determining the k<sub>on</sub> and k<sub>off</sub>.</title><p>Analysis of data from the fits in <xref ref-type="fig" rid="fig2">Figure 2A</xref>. (<bold>A</bold>) A plot of k<sub>off</sub> obtained for each injection versus [RBD]. (<bold>B</bold>) A plot of k<sub>obs</sub> for each injection versus [RBD]. The line shows a constrained fit of the equation k<sub>obs</sub> = k<sub>on</sub>*[RBD]+ k<sub>off</sub>, using the k<sub>off</sub> obtained in (<bold>A</bold>). The k<sub>on</sub> was obtained from the slope.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70658-fig2-figsupp2-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70658-fig2-figsupp2-v3.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Affinity and kinetic data for RBD variants and ACE2 variants.</title><p>Mean and SD of the k<sub>off</sub>, k<sub>on</sub>, calculated K<sub>D</sub>, and equilibrium K<sub>D</sub> values for all RBD variants binding all ACE2 variants. For most measurements n = 3, the exceptions were RBD WT/ACE2 WT equilibrium K<sub>D</sub> measurements (n = 24) and other RBD WT measurements (n = 6). UK2 refers to the VOC-202102–02 variant.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">k<sub>off</sub> (s<sup>–1</sup>)</th><th align="left" valign="bottom">SD</th><th align="left" valign="bottom">k<sub>on</sub> (µM<sup>–1</sup> s<sup>–1</sup>)</th><th align="left" valign="bottom">SD</th><th align="left" valign="bottom">K<sub>D</sub> calc. (nM)</th><th align="left" valign="bottom">SD</th><th align="left" valign="bottom">K<sub>D</sub> equi. (nM)</th><th align="left" valign="bottom">SD</th></tr></thead><tbody><tr><td align="left" valign="bottom"> <bold>RBD over WT ACE2</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">WT</td><td align="char" char="." valign="bottom">0.0668</td><td align="char" char="." valign="bottom">0.00113</td><td align="char" char="." valign="bottom">0.90</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">74.4</td><td align="char" char="." valign="bottom">4.0</td><td align="char" char="." valign="bottom">62.6</td><td align="char" char="." valign="bottom">7.7</td></tr><tr><td align="left" valign="bottom">K417N</td><td align="char" char="." valign="bottom">0.177</td><td align="char" char="." valign="bottom">0.00416</td><td align="char" char="." valign="bottom">0.49</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">364</td><td align="char" char="." valign="bottom">29</td><td align="char" char="." valign="bottom">349</td><td align="char" char="." valign="bottom">10</td></tr><tr><td align="left" valign="bottom">K417T</td><td align="char" char="." valign="bottom">0.126</td><td align="char" char="." valign="bottom">0.00510</td><td align="char" char="." valign="bottom">0.55</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="." valign="bottom">230</td><td align="char" char="." valign="bottom">23</td><td align="char" char="." valign="bottom">226</td><td align="char" char="." valign="bottom">19</td></tr><tr><td align="left" valign="bottom">S477N</td><td align="char" char="." valign="bottom">0.0348</td><td align="char" char="." valign="bottom">0.00037</td><td align="char" char="." valign="bottom">0.81</td><td align="char" char="." valign="bottom">0.03</td><td align="char" char="." valign="bottom">42.9</td><td align="char" char="." valign="bottom">2.1</td><td align="char" char="." valign="bottom">42.6</td><td align="char" char="." valign="bottom">3.0</td></tr><tr><td align="left" valign="bottom">E484K</td><td align="char" char="." valign="bottom">0.0818</td><td align="char" char="." valign="bottom">0.00183</td><td align="char" char="." valign="bottom">1.54</td><td align="char" char="." valign="bottom">0.03</td><td align="char" char="." valign="bottom">53.1</td><td align="char" char="." valign="bottom">1.7</td><td align="char" char="." valign="bottom">52.6</td><td align="char" char="." valign="bottom">2.0</td></tr><tr><td align="left" valign="bottom">N501Y (Alpha)</td><td align="char" char="." valign="bottom">0.0111</td><td align="char" char="." valign="bottom">0.00017</td><td align="char" char="." valign="bottom">1.59</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="." valign="bottom">7.0</td><td align="char" char="." valign="bottom">0.25</td><td align="char" char="." valign="bottom">5.5</td><td align="char" char="." valign="bottom">2.4</td></tr><tr><td align="left" valign="bottom">K417N/E484K</td><td align="char" char="." valign="bottom">0.251</td><td align="char" char="." valign="bottom">0.00799</td><td align="char" char="." valign="bottom">1.02</td><td align="char" char="." valign="bottom">0.07</td><td align="char" char="." valign="bottom">247</td><td align="char" char="." valign="bottom">23</td><td align="char" char="." valign="bottom">251</td><td align="char" char="." valign="bottom">23</td></tr><tr><td align="left" valign="bottom">K417T/E484K</td><td align="char" char="." valign="bottom">0.168</td><td align="char" char="." valign="bottom">0.00573</td><td align="char" char="." valign="bottom">1.10</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">153</td><td align="char" char="." valign="bottom">12</td><td align="char" char="." valign="bottom">147</td><td align="char" char="." valign="bottom">8.6</td></tr><tr><td align="left" valign="bottom">E484K/N501Y (UK2)</td><td align="char" char="." valign="bottom">0.0118</td><td align="char" char="." valign="bottom">0.00037</td><td align="char" char="." valign="bottom">2.33</td><td align="char" char="." valign="bottom">0.10</td><td align="char" char="." valign="bottom">5.1</td><td align="char" char="." valign="bottom">0.36</td><td align="char" char="." valign="bottom">3.7</td><td align="char" char="." valign="bottom">2.7</td></tr><tr><td align="left" valign="bottom">K417N/E484K/N501Y (Beta)</td><td align="char" char="." valign="bottom">0.0291</td><td align="char" char="." valign="bottom">0.00076</td><td align="char" char="." valign="bottom">1.46</td><td align="char" char="." valign="bottom">0.06</td><td align="char" char="." valign="bottom">20.0</td><td align="char" char="." valign="bottom">0.70</td><td align="char" char="." valign="bottom">17.4</td><td align="char" char="." valign="bottom">3.1</td></tr><tr><td align="left" valign="bottom">K417T/E484K/N501Y (Gamma)</td><td align="char" char="." valign="bottom">0.0211</td><td align="char" char="." valign="bottom">0.00021</td><td align="char" char="." valign="bottom">1.56</td><td align="char" char="." valign="bottom">0.07</td><td align="char" char="." valign="bottom">13.5</td><td align="char" char="." valign="bottom">0.45</td><td align="char" char="." valign="bottom">12.2</td><td align="char" char="." valign="bottom">3.4</td></tr><tr><td align="left" valign="bottom"> <bold>RBD over S19P ACE2</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">WT</td><td align="char" char="." valign="bottom">0.0298</td><td align="char" char="." valign="bottom">0.00039</td><td align="char" char="." valign="bottom">1.50</td><td align="char" char="." valign="bottom">0.12</td><td align="char" char="." valign="bottom">20.0</td><td align="char" char="." valign="bottom">1.3</td><td align="char" char="." valign="bottom">30.5</td><td align="char" char="." valign="bottom">2.2</td></tr><tr><td align="left" valign="bottom">K417N</td><td align="char" char="." valign="bottom">0.0782</td><td align="char" char="." valign="bottom">0.00284</td><td align="char" char="." valign="bottom">0.72</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="." valign="bottom">108</td><td align="char" char="." valign="bottom">2.8</td><td align="char" char="." valign="bottom">129</td><td align="char" char="." valign="bottom">8.2</td></tr><tr><td align="left" valign="bottom">K417T</td><td align="char" char="." valign="bottom">0.0521</td><td align="char" char="." valign="bottom">0.00196</td><td align="char" char="." valign="bottom">0.69</td><td align="char" char="." valign="bottom">0.02</td><td align="char" char="." valign="bottom">75.8</td><td align="char" char="." valign="bottom">4.7</td><td align="char" char="." valign="bottom">87.8</td><td align="char" char="." valign="bottom">7.0</td></tr><tr><td align="left" valign="bottom">S477N</td><td align="char" char="." valign="bottom">0.0257</td><td align="char" char="." valign="bottom">0.00016</td><td align="char" char="." valign="bottom">1.05</td><td align="char" char="." valign="bottom">0.07</td><td align="char" char="." valign="bottom">24.6</td><td align="char" char="." valign="bottom">1.7</td><td align="char" char="." valign="bottom">30.3</td><td align="char" char="." valign="bottom">2.7</td></tr><tr><td align="left" valign="bottom">E484K</td><td align="char" char="." valign="bottom">0.0325</td><td align="char" char="." valign="bottom">0.00031</td><td align="char" char="." valign="bottom">2.02</td><td align="char" char="." valign="bottom">0.08</td><td align="char" char="." valign="bottom">16.2</td><td align="char" char="." valign="bottom">0.55</td><td align="char" char="." valign="bottom">20.8</td><td align="char" char="." valign="bottom">1.3</td></tr><tr><td align="left" valign="bottom">N501Y (Alpha)</td><td align="char" char="." valign="bottom">0.0051</td><td align="char" char="." valign="bottom">0.00004</td><td align="char" char="." valign="bottom">2.31</td><td align="char" char="." valign="bottom">0.09</td><td align="char" char="." valign="bottom">2.2</td><td align="char" char="." valign="bottom">0.09</td><td align="char" char="." valign="bottom">3.5</td><td align="char" char="." valign="bottom">0.4</td></tr><tr><td align="left" valign="bottom">K417N/E484K</td><td align="char" char="." valign="bottom">0.0961</td><td align="char" char="." valign="bottom">0.00198</td><td align="char" char="." valign="bottom">1.28</td><td align="char" char="." valign="bottom">0.11</td><td align="char" char="." valign="bottom">75.6</td><td align="char" char="." valign="bottom">7.1</td><td align="char" char="." valign="bottom">91.3</td><td align="char" char="." valign="bottom">6.5</td></tr><tr><td align="left" valign="bottom">K417T/E484K</td><td align="char" char="." valign="bottom">0.0660</td><td align="char" char="." valign="bottom">0.00255</td><td align="char" char="." valign="bottom">1.45</td><td align="char" char="." valign="bottom">0.03</td><td align="char" char="." valign="bottom">45.5</td><td align="char" char="." valign="bottom">2.5</td><td align="char" char="." valign="bottom">53.8</td><td align="char" char="." valign="bottom">1.5</td></tr><tr><td align="left" valign="bottom">E484K/N501Y (UK2)</td><td align="char" char="." valign="bottom">0.0051</td><td align="char" char="." valign="bottom">0.00008</td><td align="char" char="." valign="bottom">3.10</td><td align="char" char="." valign="bottom">0.10</td><td align="char" char="." valign="bottom">1.7</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">3.4</td><td align="char" char="." valign="bottom">0.4</td></tr><tr><td align="left" valign="bottom">K417N/E484K/N501Y (Beta)</td><td align="char" char="." valign="bottom">0.0122</td><td align="char" char="." valign="bottom">0.00009</td><td align="char" char="." valign="bottom">2.16</td><td align="char" char="." valign="bottom">0.03</td><td align="char" char="." valign="bottom">5.7</td><td align="char" char="." valign="bottom">0.07</td><td align="char" char="." valign="bottom">10.4</td><td align="char" char="." valign="bottom">1.2</td></tr><tr><td align="left" valign="bottom">K417T/E484K/N501Y (Gamma)</td><td align="char" char="." valign="bottom">0.0085</td><td align="char" char="." valign="bottom">0.00007</td><td align="char" char="." valign="bottom">2.11</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">4.0</td><td align="char" char="." valign="bottom">0.07</td><td align="char" char="." valign="bottom">6.1</td><td align="char" char="." valign="bottom">1.3</td></tr><tr><td align="left" valign="bottom"><bold>RBD over K26R ACE2</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">S477N</td><td align="char" char="." valign="bottom">0.0240</td><td align="char" char="." valign="bottom">0.00009</td><td align="char" char="." valign="bottom">1.07</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">22.6</td><td align="char" char="." valign="bottom">1.1</td><td align="char" char="." valign="bottom">33.4</td><td align="char" char="." valign="bottom">1.3</td></tr><tr><td align="left" valign="bottom">WT</td><td align="char" char="." valign="bottom">0.0500</td><td align="char" char="." valign="bottom">0.00062</td><td align="char" char="." valign="bottom">1.60</td><td align="char" char="." valign="bottom">0.16</td><td align="char" char="." valign="bottom">31.4</td><td align="char" char="." valign="bottom">2.6</td><td align="char" char="." valign="bottom">48.8</td><td align="char" char="." valign="bottom">2.5</td></tr><tr><td align="left" valign="bottom">K417N</td><td align="char" char="." valign="bottom">0.154</td><td align="char" char="." valign="bottom">0.00789</td><td align="char" char="." valign="bottom">0.88</td><td align="char" char="." valign="bottom">0.07</td><td align="char" char="." valign="bottom">175</td><td align="char" char="." valign="bottom">8.1</td><td align="char" char="." valign="bottom">237</td><td align="char" char="." valign="bottom">15</td></tr><tr><td align="left" valign="bottom">K417T</td><td align="char" char="." valign="bottom">0.101</td><td align="char" char="." valign="bottom">0.00079</td><td align="char" char="." valign="bottom">0.81</td><td align="char" char="." valign="bottom">0.12</td><td align="char" char="." valign="bottom">127</td><td align="char" char="." valign="bottom">17.4</td><td align="char" char="." valign="bottom">154</td><td align="char" char="." valign="bottom">2.8</td></tr><tr><td align="left" valign="bottom">S477N</td><td align="char" char="." valign="bottom">0.0240</td><td align="char" char="." valign="bottom">0.00009</td><td align="char" char="." valign="bottom">1.07</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">22.6</td><td align="char" char="." valign="bottom">1.1</td><td align="char" char="." valign="bottom">33.4</td><td align="char" char="." valign="bottom">1.3</td></tr><tr><td align="left" valign="bottom">E484K</td><td align="char" char="." valign="bottom">0.0587</td><td align="char" char="." valign="bottom">0.00109</td><td align="char" char="." valign="bottom">2.03</td><td align="char" char="." valign="bottom">0.03</td><td align="char" char="." valign="bottom">28.9</td><td align="char" char="." valign="bottom">1.0</td><td align="char" char="." valign="bottom">35.9</td><td align="char" char="." valign="bottom">1.5</td></tr><tr><td align="left" valign="bottom">N501Y (Alpha)</td><td align="char" char="." valign="bottom">0.0081</td><td align="char" char="." valign="bottom">0.00002</td><td align="char" char="." valign="bottom">2.34</td><td align="char" char="." valign="bottom">0.09</td><td align="char" char="." valign="bottom">3.5</td><td align="char" char="." valign="bottom">0.15</td><td align="char" char="." valign="bottom">7.5</td><td align="char" char="." valign="bottom">1.5</td></tr><tr><td align="left" valign="bottom">K417N/E484K</td><td align="char" char="." valign="bottom">0.191</td><td align="char" char="." valign="bottom">0.00481</td><td align="char" char="." valign="bottom">1.48</td><td align="char" char="." valign="bottom">0.15</td><td align="char" char="." valign="bottom">130</td><td align="char" char="." valign="bottom">9.4</td><td align="char" char="." valign="bottom">166</td><td align="char" char="." valign="bottom">11</td></tr><tr><td align="left" valign="bottom">K417T/E484K</td><td align="char" char="." valign="bottom">0.135</td><td align="char" char="." valign="bottom">0.00407</td><td align="char" char="." valign="bottom">1.53</td><td align="char" char="." valign="bottom">0.02</td><td align="char" char="." valign="bottom">88.0</td><td align="char" char="." valign="bottom">3.9</td><td align="char" char="." valign="bottom">105</td><td align="char" char="." valign="bottom">0.7</td></tr><tr><td align="left" valign="bottom">E484K/N501Y (UK2)</td><td align="char" char="." valign="bottom">0.0085</td><td align="char" char="." valign="bottom">0.00018</td><td align="char" char="." valign="bottom">3.06</td><td align="char" char="." valign="bottom">0.23</td><td align="char" char="." valign="bottom">2.8</td><td align="char" char="." valign="bottom">0.17</td><td align="char" char="." valign="bottom">6.4</td><td align="char" char="." valign="bottom">0.3</td></tr><tr><td align="left" valign="bottom">K417N/E484K/N501Y (Beta)</td><td align="char" char="." valign="bottom">0.0234</td><td align="char" char="." valign="bottom">0.00040</td><td align="char" char="." valign="bottom">2.13</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">11.0</td><td align="char" char="." valign="bottom">0.28</td><td align="char" char="." valign="bottom">18.7</td><td align="char" char="." valign="bottom">2.0</td></tr><tr><td align="left" valign="bottom">K417T/E484K/N501Y (Gamma)</td><td align="char" char="." valign="bottom">0.0164</td><td align="char" char="." valign="bottom">0.00028</td><td align="char" char="." valign="bottom">2.21</td><td align="char" char="." valign="bottom">0.06</td><td align="char" char="." valign="bottom">7.4</td><td align="char" char="." valign="bottom">0.33</td><td align="char" char="." valign="bottom">15.3</td><td align="char" char="." valign="bottom">0.8</td></tr></tbody></table></table-wrap></sec><sec id="s2-3"><title>The effect of RBD mutations</title><p>We next evaluated the effect of RBD mutations on the affinity and kinetics of binding to ACE2 (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="table" rid="table1">Table 1</xref>). Example sensorgrams are shown of mutations that increased (N501Y, <xref ref-type="fig" rid="fig3">Figure 3A</xref>) or decreased (K417N, <xref ref-type="fig" rid="fig3">Figure 3B</xref>) the binding affinity, while the key results from all mutants are summarised in <xref ref-type="fig" rid="fig3">Figure 3C</xref>. The single mutations S477N, E484K, and N501Y all enhanced binding. The N501Y mutation had the biggest effect, increasing the affinity ~10 fold to K<sub>D</sub> ~7 nM, by increasing the k<sub>on</sub> ~1.8-fold and decreasing the k<sub>off</sub> by ~7-fold. The S477N and E484K mutations increased the affinity more modestly (~1.5-fold), by decreasing the k<sub>off</sub> (S477N) or increasing the k<sub>on</sub> (E484K). The K417T and K417N mutations decreased the affinity ~2- and ~ 4-fold, respectively, mainly by decreasing the k<sub>on</sub> but also by increasing the k<sub>off</sub>. Affinity-altering mutations in binding sites mainly affect the k<sub>off</sub> (<xref ref-type="bibr" rid="bib2">Agius et al., 2013</xref>) and have more modest effects on the k<sub>on</sub>. Changes in electrostatic interactions can dramatically affect the k<sub>on</sub> (<xref ref-type="bibr" rid="bib37">Schreiber and Fersht, 1996</xref>) and are a plausible explanation for the effects of the mutations K417T, K417N, and E484K on k<sub>on</sub>. K417 forms a salt bridge with D30 on ACE2 (<xref ref-type="bibr" rid="bib20">Lan et al., 2020</xref>), while E484 is ~9 Å from E75 on ACE2 (<xref ref-type="bibr" rid="bib20">Lan et al., 2020</xref>). Thus, the mutations K417N/T and E484K would decrease and increase, respectively, long-range electrostatic forces that may accelerate association (<xref ref-type="bibr" rid="bib37">Schreiber and Fersht, 1996</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Effect of RBD mutations on binding to WT ACE2.</title><p>Overlay of traces showing association and dissociation of N501Y (<bold>A</bold>) and K417N (<bold>B</bold>) RBD variants when injected at a range of concentrations over immobilised WT ACE2. The right panels show an expanded view of the dissociation phase. The blue lines show fits used for determining the k<sub>on</sub> and k<sub>off</sub>. (<bold>C</bold>) The fold change relative to WT RBD of the calculated K<sub>D</sub>, k<sub>on</sub>, and k<sub>off</sub> for binding of the indicated RBD variants to immobilised WT ACE2 (error bars show SD, n = 3). Representative sensorgrams from all mutants shown in <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>, and the mean values from multiple repeats are in <xref ref-type="table" rid="table1">Table 1</xref>. (<bold>D</bold>) The blue lines show the measured ΔΔG for indicated RBD variants. The red lines show the predicted ΔΔG for the RBD variants with multiple mutations, which were calculated by adding ΔΔG values for single mutation variants (error bars show SD, n = 3).</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70658-fig3-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70658-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Mass transport controls for RBD.</title><p>The k<sub>off</sub> (<bold>A</bold>) and k<sub>on</sub> (<bold>B</bold>) for E484K/N501Y (UK2) RBD binding WT ACE2 at a range of surface immobilisations (n = 12). UK2 refers to VOC-202102–02.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70658-fig3-figsupp1-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70658-fig3-figsupp1-v3.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Representative SPR data for RBD variants binding to WT ACE2.</title><p>Binding traces for the indicated RBD variants injected at different concentrations over immobilised WT ACE2. The right panels show an expanded view of the dissociation phase. The blue lines show fits used for determining the k<sub>on</sub> and k<sub>off</sub>. UK2 refers to the VOC-202102–02 variant.</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70658-fig3-figsupp2-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70658-fig3-figsupp2-v3.tif"/></fig></fig-group><p>We also examined the effect on ACE2 binding of combinations of RBD mutations, including combinations present in VOC-202102–02, a subset of the Alpha lineage (N501Y) with the E484K mutation (“SARS-CoV-2 Variants of concern and variants under investigation – GOV.UK,” 2021), and the Beta and Gamma variants (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). In the case of VOC-202102–02, the addition of the E484K mutation to N501Y further increased the affinity, to ~15-fold higher than WT RBD (K<sub>D</sub> ~5 nM), by further increasing the k<sub>on</sub>. Because the higher k<sub>on</sub> could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilisation (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). The affinity of the Beta (K417N/ E484K/N501Y) and Gamma (K417T/E484K/N501Y) RBD variants for ACE2 increased by 3.7- and 5.3-fold, respectively, relative to wild-type RBD, by both increasing the k<sub>on</sub> and decreasing the k<sub>off</sub> rate constants.</p><p>We next examined whether the effects of the mutations were additive, as is typically the case for multiple mutations at protein/protein interfaces (<xref ref-type="bibr" rid="bib49">Wells, 1990</xref>). To do this, we converted the changes in K<sub>D</sub> to changes in binding energy (ΔΔG, <xref ref-type="table" rid="table2">Table 2</xref>) and examined whether the ΔΔG measured for RBD variants with multiple mutations was equal to the sum of the ΔΔG values measured for the individual RBD mutants. This was indeed the case (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), indicating that the effects on each mutation are independent. This is consistent with them being spaced well apart within the interface (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) and validates the accuracy of the affinity measurements.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>ΔΔG for RBD variants binding to ACE2 variants.</title><p>Mean and SD of ΔΔG (n = 3, kcal/mol) were determined as described in Materials and methods using the calculated K<sub>D</sub> values in <xref ref-type="table" rid="table1">Table 1</xref>. UK2 refers to the VOC-202102–02 variant.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">Ace2 wt</th><th align="left" valign="bottom"/><th align="left" valign="bottom">Ace2 s19p</th><th align="left" valign="bottom"/><th align="left" valign="bottom">Ace2 k26r</th><th align="left" valign="bottom"/></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>RBD variant</bold></td><td align="left" valign="bottom"><bold>ΔΔG</bold></td><td align="left" valign="bottom"><bold>SD</bold></td><td align="left" valign="bottom"><bold>ΔΔG</bold></td><td align="left" valign="bottom"><bold>SD</bold></td><td align="left" valign="bottom"><bold>ΔΔG</bold></td><td align="left" valign="bottom"><bold>SD</bold></td></tr><tr><td align="left" valign="bottom">WT</td><td align="char" char="." valign="bottom">0.00</td><td align="char" char="." valign="bottom">0.00</td><td align="char" char="." valign="bottom">0.79</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">0.52</td><td align="char" char="." valign="bottom">0.06</td></tr><tr><td align="left" valign="bottom">K417N</td><td align="char" char="." valign="bottom">–0.96</td><td align="char" char="." valign="bottom">0.06</td><td align="char" char="." valign="bottom">–0.23</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="." valign="bottom">–0.52</td><td align="char" char="." valign="bottom">0.04</td></tr><tr><td align="left" valign="bottom">K417T</td><td align="char" char="." valign="bottom">–0.68</td><td align="char" char="." valign="bottom">0.07</td><td align="char" char="." valign="bottom">–0.01</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">–0.32</td><td align="char" char="." valign="bottom">0.09</td></tr><tr><td align="left" valign="bottom">S477N</td><td align="char" char="." valign="bottom">0.33</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="." valign="bottom">0.67</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">0.72</td><td align="char" char="." valign="bottom">0.04</td></tr><tr><td align="left" valign="bottom">E484K</td><td align="char" char="." valign="bottom">0.20</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="." valign="bottom">0.92</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="." valign="bottom">0.57</td><td align="char" char="." valign="bottom">0.04</td></tr><tr><td align="left" valign="bottom">N501Y (Alpha)</td><td align="char" char="." valign="bottom">1.43</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="." valign="bottom">2.13</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="." valign="bottom">1.86</td><td align="char" char="." valign="bottom">0.04</td></tr><tr><td align="left" valign="bottom">K417N/E484K</td><td align="char" char="." valign="bottom">–0.72</td><td align="char" char="." valign="bottom">0.07</td><td align="char" char="." valign="bottom">–0.01</td><td align="char" char="." valign="bottom">0.07</td><td align="char" char="." valign="bottom">–0.34</td><td align="char" char="." valign="bottom">0.06</td></tr><tr><td align="left" valign="bottom">K417T/E484K</td><td align="char" char="." valign="bottom">–0.43</td><td align="char" char="." valign="bottom">0.06</td><td align="char" char="." valign="bottom">0.30</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">–0.10</td><td align="char" char="." valign="bottom">0.04</td></tr><tr><td align="left" valign="bottom">E484K/N501Y (UK2)</td><td align="char" char="." valign="bottom">1.62</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">2.30</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="." valign="bottom">1.98</td><td align="char" char="." valign="bottom">0.05</td></tr><tr><td align="left" valign="bottom">K417N/E484K/N501Y (Beta)</td><td align="char" char="." valign="bottom">0.79</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="." valign="bottom">1.56</td><td align="char" char="." valign="bottom">0.03</td><td align="char" char="." valign="bottom">1.16</td><td align="char" char="." valign="bottom">0.04</td></tr><tr><td align="left" valign="bottom">K417T/E484K/N501Y (Gamma)</td><td align="char" char="." valign="bottom">1.03</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="." valign="bottom">1.76</td><td align="char" char="." valign="bottom">0.03</td><td align="char" char="." valign="bottom">1.39</td><td align="char" char="." valign="bottom">0.04</td></tr></tbody></table></table-wrap></sec><sec id="s2-4"><title>The effects of ACE2 mutations</title><p>We next examined the effects of mutations of ACE2 (S19P and K26R) on binding to both wild-type and common variants of RBD (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>, and <xref ref-type="table" rid="table1">Table 1</xref>). Both S19P and K26R increased the affinity of WT RBD binding by ~3.7- and ~ 2.4-fold (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). These increases in affinity were the result of both increases in the k<sub>on</sub> and decreases in the k<sub>off</sub>.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Effect of mutations in ACE2.</title><p>(<bold>A</bold>) The fold change relative to WT ACE2 of the calculated K<sub>D</sub>, k<sub>on</sub>, and k<sub>off</sub> for the interaction of WT RBD and the indicated ACE2 variants (error bars show SD, n = 3). (<bold>B, C</bold>) Show the difference (ΔΔΔG) between the measured and predicted ΔΔG for S19P (<bold>B</bold>) and K26R (<bold>C</bold>) ACE2 variants binding to the indicated RBD variants, calculated from data in <xref ref-type="table" rid="table2">Table 2</xref>. The predicted ΔΔG values for each variant RBD/variant ACE2 interaction were calculated from the sum of the ΔΔG for the ACE2 variant binding WT RBD and the ΔΔG for the RBD variant binding WT ACE2 (<xref ref-type="table" rid="table2">Table 2</xref>).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70658-fig4-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70658-fig4-v3.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Representative SPR data for WT RBD binding ACE2 variants.</title><p>Binding traces for the WT RBD injected at different concentrations over the indicated immobilised ACE2 variants. The right panels show an expanded view of the dissociation phase. The blue lines show fits used for determining the k<sub>on</sub> and k<sub>off</sub>.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70658-fig4-figsupp1-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70658-fig4-figsupp1-v3.tif"/></fig></fig-group><p>Finally, we looked for interactions between RBD and ACE2 mutations by measuring the effects of the ACE2 mutations on binding to all mutant forms of RBD (<xref ref-type="table" rid="table1">Table 1</xref>). After converting changes in K<sub>D</sub> to ΔΔG (<xref ref-type="table" rid="table2">Table 2</xref>), we examined whether ΔΔG measured for a given ACE2 variant/RBD variant interaction was equal to the sum of the ΔΔG measured for ACE2 variant/RBD WT and ACE WT/RBD variant interactions. This is depicted as the difference between the measured and predicted ΔΔG for interactions between ACE2 and RBD variants (ΔΔΔG in <xref ref-type="fig" rid="fig4">Figure 4B,C</xref>, <xref ref-type="bibr" rid="bib8">Dejnirattisai et al., 2021</xref>). In most cases, ΔΔΔG values were close to zero, indicating that the effects of these mutations were largely independent. The one exception was the combination of ACE2 S19P and RBD S477N variants, where the measured value was significantly lower than the predicted value (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), indicating that these mutations were not independent. This is consistent with the fact that the ACE2 residue S19 is adjacent to RBD residue S477 in the contact interface (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). An important consequence of this is that the S477N mutation increased the affinity of RBD for ACE2 WT but decreased its affinity for ACE2 S19P.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>While our finding that the SARS-CoV-2 RBD binds ACE2 with an affinity of K<sub>D</sub> 74 nM at 37°C is consistent with previous studies (K<sub>D</sub> 6–133 nM) (<xref ref-type="bibr" rid="bib19">Laffeber et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">Lei et al., 2020</xref>; <xref ref-type="bibr" rid="bib23">Liu et al., 2021</xref>; <xref ref-type="bibr" rid="bib38">Shang et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Supasa et al., 2021</xref>; <xref ref-type="bibr" rid="bib52">Wrapp et al., 2020</xref>; <xref ref-type="bibr" rid="bib56">Zhang et al., 2021</xref>; <xref ref-type="bibr" rid="bib55">Zhang et al., 2020</xref>), the rate constants that we measured (k<sub>on</sub> 0.9 μM<sup>–1</sup>.s<sup>–1</sup> and k<sub>off</sub> 0.067 s<sup>–1</sup>) were faster than all previous reports. One likely reason for this is that previous measurements were performed at a lower temperature, which almost always decreases rate constants. While some studies stated that binding constants were measured at 25°C (<xref ref-type="bibr" rid="bib19">Laffeber et al., 2021</xref>; <xref ref-type="bibr" rid="bib55">Zhang et al., 2020</xref>), most studies did not report the temperature, suggesting that they were performed at room temperature or the standard instrument temperature (20°C–25°C). A second likely reason is that previous kinetic studies were performed under conditions in which the rate of diffusion of soluble molecule to the sensor surface limits the association rate, and rebinding of dissociated molecules to the surface reduces the measured dissociation rate. These are known pitfalls of both techniques used in these studies, surface plasmon resonance (<xref ref-type="bibr" rid="bib28">Myszka, 1997</xref>), and bilayer interferometry (<xref ref-type="bibr" rid="bib1">Abdiche et al., 2008</xref>). In the present study, we avoided these issues by immobilising a very low level of ligand on the sensor surface. A third possible reason is that the proteins were aggregated, which can cause problems even when aggregates are a very minor contaminant (<xref ref-type="bibr" rid="bib43">van der Merwe and Barclay, 1996</xref>). The presence of aggregates results in complex binding kinetics, which can be excluded if the simple 1:1 Langmuir binding model fits the kinetic data. While this was demonstrated in the present study, and some previous studies (<xref ref-type="bibr" rid="bib38">Shang et al., 2020</xref>; <xref ref-type="bibr" rid="bib52">Wrapp et al., 2020</xref>; <xref ref-type="bibr" rid="bib56">Zhang et al., 2021</xref>), such fits were not shown in all studies, one of which reported more than 20-fold slower kinetics than reported here (<xref ref-type="bibr" rid="bib21">Lei et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Supasa et al., 2021</xref>).</p><p>The RBD mutations that we selected for analysis have all emerged independently and became dominant in a region at least once in different lineages, suggesting that they provide a selective advantage. Our finding that the N501Y, E484K, and S477N all increase the binding affinity of RBD for ACE2 raises the question as to whether this contributed to their selection. Several lines of evidence suggest that enhancing the Spike/ACE2 interaction would be advantageous for the virus. First, the virus has spread only very recently to humans from another mammalian host, providing insufficient time for optimisation of the affinity. Second, epidemiological studies have suggested that the Alpha variant, which has the N501Y mutation, has enhanced transmissibility (<xref ref-type="bibr" rid="bib44">Volz et al., 2021a</xref>; <xref ref-type="bibr" rid="bib48">Washington et al., 2021</xref>). Finally, a SARS-CoV-2 variant with the Spike mutation D614G, which increases its activity by stabilising it following furin cleavage (<xref ref-type="bibr" rid="bib56">Zhang et al., 2021</xref>; <xref ref-type="bibr" rid="bib55">Zhang et al., 2020</xref>), rapidly became dominant globally after it emerged (<xref ref-type="bibr" rid="bib18">Korber et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Volz et al., 2021b</xref>). Taken together, these findings suggest that the WT Spike/ACE2 interaction is limiting for transmission and that mutations that enhance it, including the N501Y, E484K, and S477N mutations, could provide a selective advantage by increasing transmissibility. This raises two questions. First, will other RBD mutations appear in SARS-CoV-2 which further enhance transmission? This seems likely, given that a large number of RBD mutations have been identified that increase the RBD/ACE2 affinity (<xref ref-type="bibr" rid="bib40">Starr et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Zahradník et al., 2021</xref>). Second, will combinations of existing mutations be selected because they further increase the affinity? While the appearance E484K, together with N501Y in three lineages (Alpha, Beta, and Gamma), supports this, it is also possible that E484K was selected because it disrupts antibody neutraliaation, as discussed below.</p><p>Our affinity and kinetic data on RBD variants are broadly consistent with some (<xref ref-type="bibr" rid="bib19">Laffeber et al., 2021</xref>; <xref ref-type="bibr" rid="bib23">Liu et al., 2021</xref>), but not all (<xref ref-type="bibr" rid="bib8">Dejnirattisai et al., 2021</xref>; <xref ref-type="bibr" rid="bib57">Zhou et al., 2021a</xref>), recent reports on the K417T/N, N501Y, and E484K variants. One caveat to our study is that we used monomeric forms of RBD and ACE2. The native Spike protein is a trimer and has several other domains, including the nearby N-teminal domain, and the native ACE2 protein can exist as a dimer (<xref ref-type="bibr" rid="bib53">Yan et al., 2020</xref>). Because of these differences, our analysis may not detect the full effects of RBD and ACE2 mutations on the Spike/ACE2 interaction. A second caveat is that we have not examined the effect of these mutations on viral attachment to cells.</p><p>Studies of other enveloped viruses, including SARS-CoV, suggest that increases in affinity of viral ligands for their cellular receptors can increase cell infection and disease severity (<xref ref-type="bibr" rid="bib13">Hasegawa et al., 2007</xref>; <xref ref-type="bibr" rid="bib22">Li et al., 2005</xref>). One study found that increasing this affinity enabled the virus to infect cells with lower receptor surface density (<xref ref-type="bibr" rid="bib13">Hasegawa et al., 2007</xref>). It follows that increases in affinity could increase the number of host tissues infected, which could increase the severity of disease (<xref ref-type="bibr" rid="bib4">Cao and Li, 2020</xref>) and/or increase the viral load in the upper respiratory tract (<xref ref-type="bibr" rid="bib15">Hoffmann et al., 2020</xref>; <xref ref-type="bibr" rid="bib51">Wölfel et al., 2020</xref>), thereby increasing spread.</p><p>Another mechanism by which mutations of RBD could provide a selective advantage is through evasion of immune responses. This is supported by the observation that neutralising antibodies present in those infected by or vaccinated against SARS-CoV-2 primarily target the RBD (<xref ref-type="bibr" rid="bib9">Garcia-Beltran et al., 2021</xref>; <xref ref-type="bibr" rid="bib10">Greaney et al., 2021a</xref>; <xref ref-type="bibr" rid="bib33">Rogers et al., 2020</xref>). Furthermore, two variants with RBD mutations that abrogate antibody neutralisation, Beta and Gamma, became dominant in regions with very high levels of prior SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib5">Cele et al., 2021</xref>; <xref ref-type="bibr" rid="bib8">Dejnirattisai et al., 2021</xref>; <xref ref-type="bibr" rid="bib16">Hoffmann et al., 2021</xref>; <xref ref-type="bibr" rid="bib34">Sabino et al., 2021</xref>; <xref ref-type="bibr" rid="bib42">Tegally et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Zhou et al., 2021b</xref>). Both lineages include the N501Y mutation, but this appears to have modest effects on antibody neutralisation (<xref ref-type="bibr" rid="bib10">Greaney et al., 2021a</xref>; <xref ref-type="bibr" rid="bib11">Greaney et al., 2021b</xref>). In contrast, the E484K mutation, also present in both variants, potently disrupts antibody neutralisation (<xref ref-type="bibr" rid="bib10">Greaney et al., 2021a</xref>; <xref ref-type="bibr" rid="bib11">Greaney et al., 2021b</xref>). Our finding that the K417N/T mutations present in Beta and Gamma variants decrease the affinity of RBD for ACE2 suggests that they were selected because they facilitate immune escape. Indeed, mutations of K417 can block antibody neutralisation, albeit less effectively than E484K (<xref ref-type="bibr" rid="bib10">Greaney et al., 2021a</xref>; <xref ref-type="bibr" rid="bib11">Greaney et al., 2021b</xref>; <xref ref-type="bibr" rid="bib47">Wang et al., 2021</xref>). It is notable that these affinity-reducing K417N/T mutations have only emerged together with mutations (N501Y and E484K) that increase the affinity of RBD for ACE2, suggesting a cooperative effect between mutations that enhance immune escape and mutations that increase affinity.</p><p>The effect of the increased affinity for SARS-CoV-2 Spike RBD of the K26R and S19P ACE2 mutants is less clear. The evidence summarised above that WT RBD/ACE2 binding is limiting for SARS-CoV-2 transmission, suggest that carriers of these ACE2 variants will be at greater risk of infection and/or severe disease. However, in contrast to SARS-CoV-2 RBD mutations, the effects of ACE2 variants are primarily relevant to the carriers of these mutations. A preliminary analysis (<xref ref-type="bibr" rid="bib24">MacGowan et al., 2021</xref>) suggests that the carriers of the K26R ACE allele might be at increased risk of severe disease, but the findings did not reach statistical significance, and further studies are required.</p><p>The interaction that we identified between the RBD S477N and ACE2 S19P mutants highlights the importance of considering variation in the host population when studying the evolution of viral variants. In this case, the opposite effect of the RBD S477N mutation on its affinity for ACE2 S19P (decreased), compared with ACE2 WT (increased), suggests that this RBD variant may have a selective disadvantage amongst carriers of the ACE2 S19P variant, in contrast to those with ACE2 WT, where it appears to be advantageous. However, the low frequency of this variant means that this is unlikely to be important at a population level and will be difficult to detect.</p><p>It is noteworthy that the two most common ACE2 variants are in positions on ACE2 with no known functional activity. This raises the question as to whether these mutations are a remnant of historic adaption to pathogens that utilised this portion of ACE2. The fact that ACE2 S19P mutation is largely confined to African/African-American populations, suggests that it is more recent than K26R and/or selected by pathogen(s) confined to the African continent.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">ACE2 WT</td><td align="left" valign="bottom">Oxford Protein Production Facility-UK</td><td align="left" valign="bottom">pOPINTTGneo_ACE2-BAP</td><td align="left" valign="bottom"> T</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">ACE2 S19P; ACE2 K26R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Available from authors</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>SARS-CoV-2</italic>)</td><td align="left" valign="bottom">RBD WT</td><td align="left" valign="bottom">BEI Resources, NIH</td><td align="left" valign="bottom">NR-52309</td><td align="left" valign="bottom">pCAGG plasmid</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>SARS-CoV-2</italic>)</td><td align="left" valign="bottom">RBD K417N; RBD RBD K417T; RBD S477N; RBD E484K; RBD N501Y; RBD K417N/E484K; RBD K417T/E484K; RBD beta; RBD gamma</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">pCAGG plasmid. Available from authors</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">pTT3-BirA-FLAG</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_64395">Addgene_64395</ext-link></td><td align="left" valign="bottom">Cotranfected for in-cell biotinylation</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">ACE2 WT; ACE2 S19P; ACE2 K26R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Expressed in HEK293 cells and purified</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">RBD WT; RBD K417N; RBD K417T; RBD S477N; RBD E484K; RBD N501Y; RBD K417N/E484K; RBD K417T/E484K; RBD beta; RBD gamma</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Expressed in HEK293 cells and purified</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-human ACE2 (mouse monoclonal)</td><td align="left" valign="bottom">NOVUS Biologicals</td><td align="left" valign="bottom">AC384</td><td align="left" valign="bottom"> (5 µg/mL)</td></tr><tr><td align="left" valign="bottom">Cell line (human)</td><td align="left" valign="bottom">FreeStyle HEK293F Cells</td><td align="left" valign="bottom">ThermoFisher Scientific</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_D603">CVCL_D603</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">FreeStyle MAX Reagent</td><td align="left" valign="bottom">ThermoFisher</td><td align="char" char="." valign="bottom">16447100</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">FreeStyle 293 Expression Medium</td><td align="left" valign="bottom">ThermoFisher</td><td align="char" char="." valign="bottom">12338018</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">commercial assay or kit</td><td align="left" valign="bottom">QuikChange II XL</td><td align="left" valign="bottom">Agilent</td><td align="char" char="." valign="bottom">200,521</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Amine coupling kit</td><td align="left" valign="bottom">Cytiva</td><td align="left" valign="bottom">BR100050</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">Prism</td><td align="left" valign="bottom">Version 9</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">CM5 sensor chips</td><td align="left" valign="bottom">Cytiva</td><td align="char" char="." valign="bottom">29149603</td><td align="left" valign="bottom"> </td></tr></tbody></table></table-wrap><sec id="s4-1"><title>ACE2 and RBD variant constructs</title><p>The plasmid used to express soluble ACE2 WT (pOPINTTGneo_ACE2-BAP), which was kindly provided by Ray Owens (Oxford Protein Production Facility-UK), encoded the following protein:</p><list list-type="bullet"><list-item><p><named-content content-type="sequence">STIEEQAKTFLDKFNHEAEDLFYQSSLASWNYNTNITEENVQNMNNAGDKWSAFLKEQSTLAQMYPLQEIQNLTVKLQLQALQQNGSSVLSEDKSKRLNTILNTMSTIYSTGKVCNPDNPQECLLLEPGLNEIMANSLDYNERLWAWESWRSEVGKQLRPLYEEYVVLKNEMARANHYEDYGDYWRGDYEVNGVDGYDYSRGQLIEDVEHTFEEIKPLYEHLHAYVRAKLMNAYPSYISPIGCLPAHLLGDMWGRFWTNLYSLTVPFGQKPNIDVTDAMVDQAWDAQRIFKEAEKFFVSVGLPNMTQGFWENSMLTDPGNVQKAVCHPTAWDLGKGDFRILMCTKVTMDDFLTAHHEMGHIQYDMAYAAQPFLLRNGANEGFHEAVGEIMSLSAATPKHLKSIGLLSPDFQEDNETEINFLLKQALTIVGTLPFTYMLEKWRWMVFKGEIPKDQWMKKWWEMKREIVGVVEPVPHDETYCDPASLFHVSNDYSFIRYYTRTLYQFQFQEALCQAAKHEGPLHKCDISNSTEAGQKLFNMLRLGKSEPWTLALENVVGAKNMNVRPLLNYFEPLFTWLKDQNKNSFVGWSTDWSPYAD<underline>LNDIFEAQKIEWHEK</underline>HHHHHH</named-content></p></list-item></list><p>The carboxy-terminal end has a biotin acceptor peptide (underlined) followed by an oligohistidine tag.</p><p>The pCAGG plasmid used to express the RBD WT construct (<xref ref-type="bibr" rid="bib3">Amanat et al., 2020</xref>) encoded the following protein:</p><list list-type="bullet"><list-item><p><named-content content-type="sequence">RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFHHHHHH</named-content></p></list-item></list><p>The carboxy-terminal end has an oligohistidine tag.</p><p>ACE2 and RBD point mutations were introduced into these plasmid constructs using the Agilent QuikChange II XL Site-Directed Mutagenesis Kit following the manufacturer’s instructions. The primers were designed using the Agilent QuikChange primer design web program.</p></sec><sec id="s4-2"><title>HEK293F cell transfection</title><p>Cells were grown in FreeStyle 293 Expression Medium (ThermoFisher Scientific, 12338018) in a 37°C incubator with 8% CO<sub>2</sub> on a shaking platform at 130 rpm. Cells were passaged every 2–3 days with the suspension volume always kept below 33.3% of the total flask capacity. The cell density was kept between 0.5 and 2 million per ml. Before transfection cells were counted to check that cell viability was above 95%, and the density was adjusted to 1.0 million per ml. For 100 ml transfection, 100 µl FreeStyle MAX Reagent (ThermoFisher Scientific, 16447100) was mixed with 2 ml Opti-MEM (ThermoFisher Scientific, 51985034) for 5 min. During this incubation, 100 µg of expression plasmid was mixed with 2 ml Opti-MEM (or in situ biotinylation of ACE2 90 µg of expression plasmid was mixed with 10 µg of expression plasmid encoding the BirA enzyme). The DNA was then mixed with the MAX Reagent and incubated for 25 min before being added to the cell culture. For ACE2 in situ biotinylation, biotin was added to the cell culture at a final concentration of 50 µM. The culture was left for 5 days for protein expression to take place.</p></sec><sec id="s4-3"><title>Protein purification</title><p>Cells were harvested by centrifugation and the supernatant collected and filtered through a 0.22 μm filter. Imidazole was added to a final concentration of 10 mM and PMSF added to a final concentration of 1 mM; 1 ml of Ni-NTA Agarose (Qiagen; 30310) was added per 100 ml of supernatant and the mix was left on a rolling platform at 4°C overnight. The mix was poured through a gravity flow column to collect the Ni-NTA Agarose. The Ni-NTA Agarose was washed three times with 25 ml of wash buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, and 20 mM imidazole at pH 8). The protein was eluted with elution buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, and 250 mM imidazole at pH 8). The protein was concentrated, and buffer exchanged into size exclusion buffer (25 mM NaH<sub>2</sub>PO<sub>4</sub> and 150 mM NaCl at pH 7.5) using a protein concentrator with a 10,000 molecular weight cut-off. The protein was concentrated down to less than 500 μl and loading onto a Superdex 200 10/300 GL (Cytiva, 17-5175-01) size exclusion column (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Fractions corresponding to the desired peak were pooled and frozen at –80°C. Samples from all observed peaks were analysed on a reducing SDS–PAGE gel (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p></sec><sec id="s4-4"><title>Surface plasmon resonance</title><p>RBD binding to ACE2 was analysed on a Biacore T200 instrument (Cytiva) at 37°C and a flow rate of 30 µl/min. Running buffer was HBS-EP (Cytiva, BR100669). Streptavidin was coupled with a CM5 sensor chip (Cytiva, 29149603) using an amine coupling kit (Cytiva, BR100050) to near saturation, typically 10,000–12,000 response units (RU). Biotinylated ACE2 WT and variants were injected into the experimental flow cells (FC2–FC4) for different lengths of time to produce desired immobilisation levels (20–800 RU). FC1 was used as a reference and contained streptavidin only. Excess streptavidin was blocked with two 40 s injections of 250 µM biotin (Avidity). Before RBD injections, the chip surface was conditioned with eight injections of the running buffer. A dilution series of RBD was then injected in all FCs. Buffer alone was injected after every two or three RBD injections. The length of all injections was 30 s, and dissociation was monitored for 180–670 s. The background response measured in FC1 was subtracted from the response in the other three FCs. In addition, the responses measured during buffer injections closest in time were subtracted. Such double-referencing improves data quality when binding responses are low as needed to obtain accurate kinetic data (<xref ref-type="bibr" rid="bib29">Myszka, 1999</xref>). At the end of each experiment, an ACE2-specific mouse monoclonal antibody (NOVUS Biologicals, AC384) was injected at 5 µg/ml for 10 min to confirm the presence and relative amounts of immobilised ACE2.</p></sec><sec id="s4-5"><title>Data analysis</title><p>Double-referenced binding data was fitted using GraphPad Prism. The k<sub>off</sub> was determined by fitting a mono-exponential decay curve to data from the dissociation phase of each injection. The k<sub>off</sub> from four to six RBD injections was averaged (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). The k<sub>on</sub> was determined by first fitting a mono-exponential association curve to data from the association phase, yielding the k<sub>obs</sub>, and then plotting the k<sub>obs</sub> vs the concentration of RBD and performing a linear fit of the equation k<sub>obs</sub> = k<sub>on</sub>*[RBD]+ k<sub>off</sub> to this data (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>), using the k<sub>off</sub> determined as above to constrain the fit.</p><p>The K<sub>D</sub> was either calculated (calculated K<sub>D</sub> = k<sub>off</sub>/k<sub>on</sub>) or measured directly (equilibrium K<sub>D</sub>) as follows. Equilibrium binding levels at a given [RBD] were determined from the fit of the mono-exponential association phase model to the association phase data. These equilibrium binding levels were plotted against [RBD], and a fit of the simple 1:1 Langmuir binding model to this data was used to determine the equilibrium K<sub>D</sub> (<xref ref-type="fig" rid="fig2">Figure 2D</xref>).</p><p>ΔG for each affinity measurement was calculated from the relationship ΔG = R*T*lnK<sub>D</sub>, where <italic>R</italic> = 1.987 cal mol<sup>–1</sup> K<sup>–1</sup>, T = 310.18 K, and K<sub>D</sub> is in units M. ΔΔG values (<xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3D</xref>) were calculated for each mutant from the relationship ΔΔG = ΔG<sub>WT</sub> – DG<sub>M</sub>. The predicted ΔΔG for interactions with multiple mutants were calculated by adding the single mutant ΔΔG values (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). The difference between the measured and predicted ΔΔG (ΔΔΔG) for interactions between the ACE2 and RBD mutants was calculates as ΔΔΔG = measured ΔΔG – predicted ΔΔG (<xref ref-type="fig" rid="fig4">Figure 4B</xref>).</p><p>All errors represent standard deviations and errors for calculated values were determined by error propagation.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>Own shares in BioNTech SE</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Investigation, Methodology, Project administration, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology, Supervision</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Funding acquisition, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Resources, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Formal analysis, Funding acquisition, Supervision, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-70658-transrepform1-v3.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated and analysed during this study are included in the manuscript and supporting files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Johannes Pettmann for help with protein expression and Anna Huhn for help with data analysis. OD is supported by a Wellcome Trust Senior Fellowship in Basic Biomedical Sciences (207537/Z/17/Z828). SM and GB are supported by Biotechnology and Biological Sciences Research Council Grants (BB/J019364/1 and BB/R014752/1) and a Wellcome Trust Biomedical Resources Grant (101651/Z/13/Z).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdiche</surname><given-names>Y</given-names></name><name><surname>Malashock</surname><given-names>D</given-names></name><name><surname>Pinkerton</surname><given-names>A</given-names></name><name><surname>Pons</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the octet</article-title><source>Analytical Biochemistry</source><volume>377</volume><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2008.03.035</pub-id><pub-id pub-id-type="pmid">18405656</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agius</surname><given-names>R</given-names></name><name><surname>Torchala</surname><given-names>M</given-names></name><name><surname>Moal</surname><given-names>IH</given-names></name><name><surname>Fernández-Recio</surname><given-names>J</given-names></name><name><surname>Bates</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Characterizing changes in the rate of protein-protein dissociation upon interface mutation using hotspot energy and organization</article-title><source>PLOS Computational Biology</source><volume>9</volume><elocation-id>e1003216</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1003216</pub-id><pub-id pub-id-type="pmid">24039569</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amanat</surname><given-names>F</given-names></name><name><surname>Stadlbauer</surname><given-names>D</given-names></name><name><surname>Strohmeier</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>THO</given-names></name><name><surname>Chromikova</surname><given-names>V</given-names></name><name><surname>McMahon</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>K</given-names></name><name><surname>Arunkumar</surname><given-names>GA</given-names></name><name><surname>Jurczyszak</surname><given-names>D</given-names></name><name><surname>Polanco</surname><given-names>J</given-names></name><name><surname>Bermudez-Gonzalez</surname><given-names>M</given-names></name><name><surname>Kleiner</surname><given-names>G</given-names></name><name><surname>Aydillo</surname><given-names>T</given-names></name><name><surname>Miorin</surname><given-names>L</given-names></name><name><surname>Fierer</surname><given-names>DS</given-names></name><name><surname>Lugo</surname><given-names>LA</given-names></name><name><surname>Kojic</surname><given-names>EM</given-names></name><name><surname>Stoever</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>STH</given-names></name><name><surname>Cunningham-Rundles</surname><given-names>C</given-names></name><name><surname>Felgner</surname><given-names>PL</given-names></name><name><surname>Moran</surname><given-names>T</given-names></name><name><surname>García-Sastre</surname><given-names>A</given-names></name><name><surname>Caplivski</surname><given-names>D</given-names></name><name><surname>Cheng</surname><given-names>AC</given-names></name><name><surname>Kedzierska</surname><given-names>K</given-names></name><name><surname>Vapalahti</surname><given-names>O</given-names></name><name><surname>Hepojoki</surname><given-names>JM</given-names></name><name><surname>Simon</surname><given-names>V</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A serological assay to detect sars-cov-2 seroconversion in humans</article-title><source>Nature Medicine</source><volume>26</volume><fpage>1033</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0913-5</pub-id><pub-id pub-id-type="pmid">32398876</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Covid-19: Towards understanding of pathogenesis</article-title><source>Cell Research</source><volume>30</volume><fpage>367</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0327-4</pub-id><pub-id pub-id-type="pmid">32346073</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cele</surname><given-names>S</given-names></name><name><surname>Gazy</surname><given-names>I</given-names></name><name><surname>Jackson</surname><given-names>L</given-names></name><name><surname>Hwa</surname><given-names>S-H</given-names></name><name><surname>Tegally</surname><given-names>H</given-names></name><name><surname>Lustig</surname><given-names>G</given-names></name><name><surname>Giandhari</surname><given-names>J</given-names></name><name><surname>Pillay</surname><given-names>S</given-names></name><name><surname>Wilkinson</surname><given-names>E</given-names></name><name><surname>Naidoo</surname><given-names>Y</given-names></name><name><surname>Karim</surname><given-names>F</given-names></name><name><surname>Ganga</surname><given-names>Y</given-names></name><name><surname>Khan</surname><given-names>K</given-names></name><name><surname>Bernstein</surname><given-names>M</given-names></name><name><surname>Balazs</surname><given-names>AB</given-names></name><name><surname>Gosnell</surname><given-names>BI</given-names></name><name><surname>Hanekom</surname><given-names>W</given-names></name><name><surname>Moosa</surname><given-names>M-YS</given-names></name><collab>Network for Genomic Surveillance in South Africa</collab><collab>COMMIT-KZN Team</collab><name><surname>Lessells</surname><given-names>RJ</given-names></name><name><surname>de Oliveira</surname><given-names>T</given-names></name><name><surname>Sigal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Escape of SARS-COV-2 501y.V2 from neutralization by convalescent plasma</article-title><source>Nature</source><volume>593</volume><fpage>142</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03471-w</pub-id><pub-id pub-id-type="pmid">33780970</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darby</surname><given-names>AC</given-names></name><name><surname>Hiscox</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Covid-19: Variants and vaccination</article-title><source>BMJ</source><volume>372</volume><elocation-id>n771</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.n771</pub-id><pub-id pub-id-type="pmid">33757984</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>NG</given-names></name><name><surname>Abbott</surname><given-names>S</given-names></name><name><surname>Barnard</surname><given-names>RC</given-names></name><name><surname>Jarvis</surname><given-names>CI</given-names></name><name><surname>Kucharski</surname><given-names>AJ</given-names></name><name><surname>Munday</surname><given-names>JD</given-names></name><name><surname>Pearson</surname><given-names>CAB</given-names></name><name><surname>Russell</surname><given-names>TW</given-names></name><name><surname>Tully</surname><given-names>DC</given-names></name><name><surname>Washburne</surname><given-names>AD</given-names></name><name><surname>Wenseleers</surname><given-names>T</given-names></name><name><surname>Gimma</surname><given-names>A</given-names></name><name><surname>Waites</surname><given-names>W</given-names></name><name><surname>Wong</surname><given-names>KLM</given-names></name><name><surname>van Zandvoort</surname><given-names>K</given-names></name><name><surname>Silverman</surname><given-names>JD</given-names></name><collab>CMMID COVID-19 Working Group</collab><collab>COVID-19 Genomics UK (COG-UK) Consortium</collab><name><surname>Diaz-Ordaz</surname><given-names>K</given-names></name><name><surname>Keogh</surname><given-names>R</given-names></name><name><surname>Eggo</surname><given-names>RM</given-names></name><name><surname>Funk</surname><given-names>S</given-names></name><name><surname>Jit</surname><given-names>M</given-names></name><name><surname>Atkins</surname><given-names>KE</given-names></name><name><surname>Edmunds</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Estimated transmissibility and impact of SARS-COV-2 lineage b.1.1.7 in England</article-title><source>Science</source><volume>372</volume><elocation-id>abg3055</elocation-id><pub-id pub-id-type="doi">10.1126/science.abg3055</pub-id><pub-id pub-id-type="pmid">33658326</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dejnirattisai</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Supasa</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Mentzer</surname><given-names>AJ</given-names></name><name><surname>Ginn</surname><given-names>HM</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Duyvesteyn</surname><given-names>HME</given-names></name><name><surname>Tuekprakhon</surname><given-names>A</given-names></name><name><surname>Nutalai</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>López-Camacho</surname><given-names>C</given-names></name><name><surname>Slon-Campos</surname><given-names>J</given-names></name><name><surname>Walter</surname><given-names>TS</given-names></name><name><surname>Skelly</surname><given-names>D</given-names></name><name><surname>Costa Clemens</surname><given-names>SA</given-names></name><name><surname>Naveca</surname><given-names>FG</given-names></name><name><surname>Nascimento</surname><given-names>V</given-names></name><name><surname>Nascimento</surname><given-names>F</given-names></name><name><surname>Fernandes da Costa</surname><given-names>C</given-names></name><name><surname>Resende</surname><given-names>PC</given-names></name><name><surname>Pauvolid-Correa</surname><given-names>A</given-names></name><name><surname>Siqueira</surname><given-names>MM</given-names></name><name><surname>Dold</surname><given-names>C</given-names></name><name><surname>Levin</surname><given-names>R</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><name><surname>Pollard</surname><given-names>AJ</given-names></name><name><surname>Knight</surname><given-names>JC</given-names></name><name><surname>Crook</surname><given-names>D</given-names></name><name><surname>Lambe</surname><given-names>T</given-names></name><name><surname>Clutterbuck</surname><given-names>E</given-names></name><name><surname>Bibi</surname><given-names>S</given-names></name><name><surname>Flaxman</surname><given-names>A</given-names></name><name><surname>Bittaye</surname><given-names>M</given-names></name><name><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name><name><surname>Gilbert</surname><given-names>SC</given-names></name><name><surname>Carroll</surname><given-names>MW</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Barnes</surname><given-names>E</given-names></name><name><surname>Dunachie</surname><given-names>SJ</given-names></name><name><surname>Paterson</surname><given-names>NG</given-names></name><name><surname>Williams</surname><given-names>MA</given-names></name><name><surname>Hall</surname><given-names>DR</given-names></name><name><surname>Hulswit</surname><given-names>RJG</given-names></name><name><surname>Bowden</surname><given-names>TA</given-names></name><name><surname>Fry</surname><given-names>EE</given-names></name><name><surname>Mongkolsapaya</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Stuart</surname><given-names>DI</given-names></name><name><surname>Screaton</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Antibody evasion by the p.1 strain of SARS-COV-2</article-title><source>Cell</source><volume>184</volume><fpage>2939</fpage><lpage>2954</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.03.055</pub-id><pub-id pub-id-type="pmid">33852911</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Beltran</surname><given-names>WF</given-names></name><name><surname>Lam</surname><given-names>EC</given-names></name><name><surname>KSt</surname><given-names>D</given-names></name><name><surname>Nitido</surname><given-names>AD</given-names></name><name><surname>Garcia</surname><given-names>ZH</given-names></name><name><surname>Hauser</surname><given-names>BM</given-names></name><name><surname>Feldman</surname><given-names>J</given-names></name><name><surname>Pavlovic</surname><given-names>MN</given-names></name><name><surname>Gregory</surname><given-names>DJ</given-names></name><name><surname>Poznansky</surname><given-names>MC</given-names></name><name><surname>Sigal</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Iafrate</surname><given-names>AJ</given-names></name><name><surname>Naranbhai</surname><given-names>V</given-names></name><name><surname>Balazs</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity</article-title><source>Cell</source><volume>184</volume><fpage>2372</fpage><lpage>2383</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.03.013</pub-id><pub-id pub-id-type="pmid">33743213</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greaney</surname><given-names>AJ</given-names></name><name><surname>Loes</surname><given-names>AN</given-names></name><name><surname>Crawford</surname><given-names>KHD</given-names></name><name><surname>Starr</surname><given-names>TN</given-names></name><name><surname>Malone</surname><given-names>KD</given-names></name><name><surname>Chu</surname><given-names>HY</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies</article-title><source>Cell Host Microbe</source><volume>29</volume><fpage>463</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2021.02.003</pub-id><pub-id pub-id-type="pmid">33592168</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greaney</surname><given-names>AJ</given-names></name><name><surname>Starr</surname><given-names>TN</given-names></name><name><surname>Gilchuk</surname><given-names>P</given-names></name><name><surname>Zost</surname><given-names>SJ</given-names></name><name><surname>Binshtein</surname><given-names>E</given-names></name><name><surname>Loes</surname><given-names>AN</given-names></name><name><surname>Hilton</surname><given-names>SK</given-names></name><name><surname>Huddleston</surname><given-names>J</given-names></name><name><surname>Eguia</surname><given-names>R</given-names></name><name><surname>Crawford</surname><given-names>KHD</given-names></name><name><surname>Dingens</surname><given-names>AS</given-names></name><name><surname>Nargi</surname><given-names>RS</given-names></name><name><surname>Sutton</surname><given-names>RE</given-names></name><name><surname>Suryadevara</surname><given-names>N</given-names></name><name><surname>Rothlauf</surname><given-names>PW</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Whelan</surname><given-names>SPJ</given-names></name><name><surname>Carnahan</surname><given-names>RH</given-names></name><name><surname>Crowe</surname><given-names>JE</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition</article-title><source>Cell Host Microbe</source><volume>29</volume><fpage>44</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.11.007</pub-id><pub-id pub-id-type="pmid">33259788</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadfield</surname><given-names>J</given-names></name><name><surname>Megill</surname><given-names>C</given-names></name><name><surname>Bell</surname><given-names>SM</given-names></name><name><surname>Huddleston</surname><given-names>J</given-names></name><name><surname>Potter</surname><given-names>B</given-names></name><name><surname>Callender</surname><given-names>C</given-names></name><name><surname>Sagulenko</surname><given-names>P</given-names></name><name><surname>Bedford</surname><given-names>T</given-names></name><name><surname>Neher</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Nextstrain: real-time tracking of pathogen evolution</article-title><source>Bioinformatics</source><volume>34</volume><fpage>4121</fpage><lpage>4123</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty407</pub-id><pub-id pub-id-type="pmid">29790939</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Marks</surname><given-names>JD</given-names></name><name><surname>Russell</surname><given-names>SJ</given-names></name><name><surname>Peng</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Affinity thresholds for membrane fusion triggering by viral glycoproteins</article-title><source>Journal of Virology</source><volume>81</volume><fpage>13149</fpage><lpage>13157</lpage><pub-id pub-id-type="doi">10.1128/jvi.01415-07</pub-id><pub-id pub-id-type="pmid">17804513</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Hodcroft</surname><given-names>EB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Covariants: SARS-COV-2 mutations and variants of interest</article-title><ext-link ext-link-type="uri" xlink:href="https://covariants.org/">https://covariants.org/</ext-link><date-in-citation iso-8601-date="2021-04-15">April 15, 2021</date-in-citation></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Krüger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><name><surname>Schiergens</surname><given-names>TS</given-names></name><name><surname>Herrler</surname><given-names>G</given-names></name><name><surname>N-H</surname><given-names>W</given-names></name><name><surname>Nitsche</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>MA</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Pöhlmann</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title><source>Cell</source><volume>181</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Arora</surname><given-names>P</given-names></name><name><surname>Groß</surname><given-names>R</given-names></name><name><surname>Seidel</surname><given-names>A</given-names></name><name><surname>Hörnich</surname><given-names>BF</given-names></name><name><surname>Hahn</surname><given-names>AS</given-names></name><name><surname>Krüger</surname><given-names>N</given-names></name><name><surname>Graichen</surname><given-names>L</given-names></name><name><surname>Hofmann-Winkler</surname><given-names>H</given-names></name><name><surname>Kempf</surname><given-names>A</given-names></name><name><surname>Winkler</surname><given-names>MS</given-names></name><name><surname>Schulz</surname><given-names>S</given-names></name><name><surname>Jäck</surname><given-names>HM</given-names></name><name><surname>Jahrsdörfer</surname><given-names>B</given-names></name><name><surname>Schrezenmeier</surname><given-names>H</given-names></name><name><surname>Müller</surname><given-names>M</given-names></name><name><surname>Kleger</surname><given-names>A</given-names></name><name><surname>Münch</surname><given-names>J</given-names></name><name><surname>Pöhlmann</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies</article-title><source>Cell</source><volume>184</volume><fpage>2384</fpage><lpage>2393</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.03.036</pub-id><pub-id pub-id-type="pmid">33794143</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>Francioli</surname><given-names>LC</given-names></name><name><surname>Tiao</surname><given-names>G</given-names></name><name><surname>Cummings</surname><given-names>BB</given-names></name><name><surname>Alföldi</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Collins</surname><given-names>RL</given-names></name><name><surname>Laricchia</surname><given-names>KM</given-names></name><name><surname>Ganna</surname><given-names>A</given-names></name><name><surname>Birnbaum</surname><given-names>DP</given-names></name><name><surname>Gauthier</surname><given-names>LD</given-names></name><name><surname>Brand</surname><given-names>H</given-names></name><name><surname>Solomonson</surname><given-names>M</given-names></name><name><surname>Watts</surname><given-names>NA</given-names></name><name><surname>Rhodes</surname><given-names>D</given-names></name><name><surname>Singer-Berk</surname><given-names>M</given-names></name><name><surname>England</surname><given-names>EM</given-names></name><name><surname>Seaby</surname><given-names>EG</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Walters</surname><given-names>RK</given-names></name><name><surname>Tashman</surname><given-names>K</given-names></name><name><surname>Farjoun</surname><given-names>Y</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Poterba</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Seed</surname><given-names>C</given-names></name><name><surname>Whiffin</surname><given-names>N</given-names></name><name><surname>Chong</surname><given-names>JX</given-names></name><name><surname>Samocha</surname><given-names>KE</given-names></name><name><surname>Pierce-Hoffman</surname><given-names>E</given-names></name><name><surname>Zappala</surname><given-names>Z</given-names></name><name><surname>O’Donnell-Luria</surname><given-names>AH</given-names></name><name><surname>Minikel</surname><given-names>EV</given-names></name><name><surname>Weisburd</surname><given-names>B</given-names></name><name><surname>Lek</surname><given-names>M</given-names></name><name><surname>Ware</surname><given-names>JS</given-names></name><name><surname>Vittal</surname><given-names>C</given-names></name><name><surname>Armean</surname><given-names>IM</given-names></name><name><surname>Bergelson</surname><given-names>L</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Connolly</surname><given-names>KM</given-names></name><name><surname>Covarrubias</surname><given-names>M</given-names></name><name><surname>Donnelly</surname><given-names>S</given-names></name><name><surname>Ferriera</surname><given-names>S</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Gentry</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Jeandet</surname><given-names>T</given-names></name><name><surname>Kaplan</surname><given-names>D</given-names></name><name><surname>Llanwarne</surname><given-names>C</given-names></name><name><surname>Munshi</surname><given-names>R</given-names></name><name><surname>Novod</surname><given-names>S</given-names></name><name><surname>Petrillo</surname><given-names>N</given-names></name><name><surname>Roazen</surname><given-names>D</given-names></name><name><surname>Ruano-Rubio</surname><given-names>V</given-names></name><name><surname>Saltzman</surname><given-names>A</given-names></name><name><surname>Schleicher</surname><given-names>M</given-names></name><name><surname>Soto</surname><given-names>J</given-names></name><name><surname>Tibbetts</surname><given-names>K</given-names></name><name><surname>Tolonen</surname><given-names>C</given-names></name><name><surname>Wade</surname><given-names>G</given-names></name><name><surname>Talkowski</surname><given-names>ME</given-names></name><name><surname>Salinas</surname><given-names>CAA</given-names></name><name><surname>Ahmad</surname><given-names>T</given-names></name><name><surname>Albert</surname><given-names>CM</given-names></name><name><surname>Ardissino</surname><given-names>D</given-names></name><name><surname>Atzmon</surname><given-names>G</given-names></name><name><surname>Barnard</surname><given-names>J</given-names></name><name><surname>Beaugerie</surname><given-names>L</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Bonnycastle</surname><given-names>LL</given-names></name><name><surname>Bottinger</surname><given-names>EP</given-names></name><name><surname>Bowden</surname><given-names>DW</given-names></name><name><surname>Bown</surname><given-names>MJ</given-names></name><name><surname>Chambers</surname><given-names>JC</given-names></name><name><surname>Chan</surname><given-names>JC</given-names></name><name><surname>Chasman</surname><given-names>D</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Chung</surname><given-names>MK</given-names></name><name><surname>Cohen</surname><given-names>B</given-names></name><name><surname>Correa</surname><given-names>A</given-names></name><name><surname>Dabelea</surname><given-names>D</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Darbar</surname><given-names>D</given-names></name><name><surname>Duggirala</surname><given-names>R</given-names></name><name><surname>Dupuis</surname><given-names>J</given-names></name><name><surname>Ellinor</surname><given-names>PT</given-names></name><name><surname>Elosua</surname><given-names>R</given-names></name><name><surname>Erdmann</surname><given-names>J</given-names></name><name><surname>Esko</surname><given-names>T</given-names></name><name><surname>Färkkilä</surname><given-names>M</given-names></name><name><surname>Florez</surname><given-names>J</given-names></name><name><surname>Franke</surname><given-names>A</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Glaser</surname><given-names>B</given-names></name><name><surname>Glatt</surname><given-names>SJ</given-names></name><name><surname>Goldstein</surname><given-names>D</given-names></name><name><surname>Gonzalez</surname><given-names>C</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name><name><surname>Haiman</surname><given-names>C</given-names></name><name><surname>Hanis</surname><given-names>C</given-names></name><name><surname>Harms</surname><given-names>M</given-names></name><name><surname>Hiltunen</surname><given-names>M</given-names></name><name><surname>Holi</surname><given-names>MM</given-names></name><name><surname>Hultman</surname><given-names>CM</given-names></name><name><surname>Kallela</surname><given-names>M</given-names></name><name><surname>Kaprio</surname><given-names>J</given-names></name><name><surname>Kathiresan</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>BJ</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Kirov</surname><given-names>G</given-names></name><name><surname>Kooner</surname><given-names>J</given-names></name><name><surname>Koskinen</surname><given-names>S</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Kugathasan</surname><given-names>S</given-names></name><name><surname>Kwak</surname><given-names>SH</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Lehtimäki</surname><given-names>T</given-names></name><name><surname>Loos</surname><given-names>RJF</given-names></name><name><surname>Lubitz</surname><given-names>SA</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name><name><surname>Marrugat</surname><given-names>J</given-names></name><name><surname>Mattila</surname><given-names>KM</given-names></name><name><surname>McCarroll</surname><given-names>S</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>McGovern</surname><given-names>D</given-names></name><name><surname>McPherson</surname><given-names>R</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>Melander</surname><given-names>O</given-names></name><name><surname>Metspalu</surname><given-names>A</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Nilsson</surname><given-names>PM</given-names></name><name><surname>O’Donovan</surname><given-names>MC</given-names></name><name><surname>Ongur</surname><given-names>D</given-names></name><name><surname>Orozco</surname><given-names>L</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>Palmer</surname><given-names>CNA</given-names></name><name><surname>Palotie</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Pato</surname><given-names>C</given-names></name><name><surname>Pulver</surname><given-names>AE</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name><name><surname>Remes</surname><given-names>AM</given-names></name><name><surname>Rioux</surname><given-names>JD</given-names></name><name><surname>Ripatti</surname><given-names>S</given-names></name><name><surname>Roden</surname><given-names>DM</given-names></name><name><surname>Saleheen</surname><given-names>D</given-names></name><name><surname>Salomaa</surname><given-names>V</given-names></name><name><surname>Samani</surname><given-names>NJ</given-names></name><name><surname>Scharf</surname><given-names>J</given-names></name><name><surname>Schunkert</surname><given-names>H</given-names></name><name><surname>Shoemaker</surname><given-names>MB</given-names></name><name><surname>Sklar</surname><given-names>P</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Sokol</surname><given-names>H</given-names></name><name><surname>Spector</surname><given-names>T</given-names></name><name><surname>Sullivan</surname><given-names>PF</given-names></name><name><surname>Suvisaari</surname><given-names>J</given-names></name><name><surname>Tai</surname><given-names>ES</given-names></name><name><surname>Teo</surname><given-names>YY</given-names></name><name><surname>Tiinamaija</surname><given-names>T</given-names></name><name><surname>Tsuang</surname><given-names>M</given-names></name><name><surname>Turner</surname><given-names>D</given-names></name><name><surname>Tusie-Luna</surname><given-names>T</given-names></name><name><surname>Vartiainen</surname><given-names>E</given-names></name><name><surname>Vawter</surname><given-names>MP</given-names></name><name><surname>Ware</surname><given-names>JS</given-names></name><name><surname>Watkins</surname><given-names>H</given-names></name><name><surname>Weersma</surname><given-names>RK</given-names></name><name><surname>Wessman</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>JG</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title><source>Nature</source><volume>581</volume><fpage>434</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2308-7</pub-id><pub-id pub-id-type="pmid">32461654</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korber</surname><given-names>B</given-names></name><name><surname>Fischer</surname><given-names>WM</given-names></name><name><surname>Gnanakaran</surname><given-names>S</given-names></name><name><surname>Yoon</surname><given-names>H</given-names></name><name><surname>Theiler</surname><given-names>J</given-names></name><name><surname>Abfalterer</surname><given-names>W</given-names></name><name><surname>Hengartner</surname><given-names>N</given-names></name><name><surname>Giorgi</surname><given-names>EE</given-names></name><name><surname>Bhattacharya</surname><given-names>T</given-names></name><name><surname>Foley</surname><given-names>B</given-names></name><name><surname>Hastie</surname><given-names>KM</given-names></name><name><surname>Parker</surname><given-names>MD</given-names></name><name><surname>Partridge</surname><given-names>DG</given-names></name><name><surname>Evans</surname><given-names>CM</given-names></name><name><surname>Freeman</surname><given-names>TM</given-names></name><name><surname>de Silva</surname><given-names>TI</given-names></name><collab>Sheffield COVID-19 Genomics Group</collab><name><surname>McDanal</surname><given-names>C</given-names></name><name><surname>Perez</surname><given-names>LG</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Moon-Walker</surname><given-names>A</given-names></name><name><surname>Whelan</surname><given-names>SP</given-names></name><name><surname>LaBranche</surname><given-names>CC</given-names></name><name><surname>Saphire</surname><given-names>EO</given-names></name><name><surname>Montefiori</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tracking changes in sars-cov-2 spike: Evidence that d614g increases infectivity of the COVID-19 virus</article-title><source>Cell</source><volume>182</volume><fpage>812</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.043</pub-id><pub-id pub-id-type="pmid">32697968</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laffeber</surname><given-names>C</given-names></name><name><surname>de Koning</surname><given-names>K</given-names></name><name><surname>Kanaar</surname><given-names>R</given-names></name><name><surname>Lebbink</surname><given-names>JHG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Experimental evidence for enhanced receptor binding by rapidly spreading SARS-COV-2 variants</article-title><source>Journal of Molecular Biology</source><volume>433</volume><elocation-id>167058</elocation-id><pub-id pub-id-type="doi">10.1016/j.jmb.2021.167058</pub-id><pub-id pub-id-type="pmid">34023401</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Shan</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure of the SARS-COV-2 spike receptor-binding domain bound to the ace2 receptor</article-title><source>Nature</source><volume>581</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2180-5</pub-id><pub-id pub-id-type="pmid">32225176</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>C</given-names></name><name><surname>Qian</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Ding</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Neutralization of SARS-COV-2 spike pseudotyped virus by recombinant ACE2-IG</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2070</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-16048-4</pub-id><pub-id pub-id-type="pmid">32332765</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Sui</surname><given-names>J</given-names></name><name><surname>Kuhn</surname><given-names>JH</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Luo</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>S-K</given-names></name><name><surname>Huang</surname><given-names>I-C</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Vasilieva</surname><given-names>N</given-names></name><name><surname>Murakami</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Marasco</surname><given-names>WA</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Choe</surname><given-names>H</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2</article-title><source>The EMBO Journal</source><volume>24</volume><fpage>1634</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600640</pub-id><pub-id pub-id-type="pmid">15791205</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Wei</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Aviszus</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Downing</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Liang</surname><given-names>B</given-names></name><name><surname>Reynoso</surname><given-names>L</given-names></name><name><surname>Downey</surname><given-names>GP</given-names></name><name><surname>Frankel</surname><given-names>SK</given-names></name><name><surname>Kappler</surname><given-names>J</given-names></name><name><surname>Marrack</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The basis of a more contagious 501y.V1 variant of sars-cov-2</article-title><source>Cell Research</source><volume>31</volume><fpage>720</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1038/s41422-021-00496-8</pub-id><pub-id pub-id-type="pmid">33893398</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>MacGowan</surname><given-names>SA</given-names></name><name><surname>Barton</surname><given-names>MI</given-names></name><name><surname>Kutuzov</surname><given-names>M</given-names></name><name><surname>Dushek</surname><given-names>O</given-names></name><name><surname>Van der</surname><given-names>M</given-names></name><name><surname>Barton</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Missense Variants in Human Ace2 Modify Binding to SARS-COV-2 Spike</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.05.21.445118</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madhi</surname><given-names>SA</given-names></name><name><surname>Izu</surname><given-names>A</given-names></name><name><surname>Pollard</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant</article-title><source>The New England Journal of Medicine</source><volume>385</volume><fpage>571</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2110093</pub-id><pub-id pub-id-type="pmid">34289271</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Madhi</surname><given-names>SA</given-names></name><name><surname>Baillie</surname><given-names>V</given-names></name><name><surname>Cutland</surname><given-names>CL</given-names></name><name><surname>Voysey</surname><given-names>M</given-names></name><name><surname>Koen</surname><given-names>AL</given-names></name><name><surname>Fairlie</surname><given-names>L</given-names></name><name><surname>Padayachee</surname><given-names>SD</given-names></name><name><surname>Dheda</surname><given-names>K</given-names></name><name><surname>Barnabas</surname><given-names>SL</given-names></name><name><surname>Bhorat</surname><given-names>QE</given-names></name><name><surname>Briner</surname><given-names>C</given-names></name><name><surname>Kwatra</surname><given-names>G</given-names></name><name><surname>Ahmed</surname><given-names>K</given-names></name><name><surname>Aley</surname><given-names>P</given-names></name><name><surname>Bhikha</surname><given-names>S</given-names></name><name><surname>Bhiman</surname><given-names>JN</given-names></name><name><surname>Bhorat</surname><given-names>AE</given-names></name><name><surname>du</surname><given-names>PJ</given-names></name><name><surname>Esmail</surname><given-names>A</given-names></name><name><surname>Groenewald</surname><given-names>M</given-names></name><name><surname>Horne</surname><given-names>E</given-names></name><name><surname>Hwa</surname><given-names>SH</given-names></name><name><surname>Jose</surname><given-names>A</given-names></name><name><surname>Lambe</surname><given-names>T</given-names></name><name><surname>Laubscher</surname><given-names>M</given-names></name><name><surname>Malahleha</surname><given-names>M</given-names></name><name><surname>Masenya</surname><given-names>M</given-names></name><name><surname>Masilela</surname><given-names>M</given-names></name><name><surname>McKenzie</surname><given-names>S</given-names></name><name><surname>Molapo</surname><given-names>K</given-names></name><name><surname>Moultrie</surname><given-names>A</given-names></name><name><surname>Oelofse</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>F</given-names></name><name><surname>Pillay</surname><given-names>S</given-names></name><name><surname>Rhead</surname><given-names>S</given-names></name><name><surname>Rodel</surname><given-names>H</given-names></name><name><surname>Rossouw</surname><given-names>L</given-names></name><name><surname>Taoushanis</surname><given-names>C</given-names></name><name><surname>Tegally</surname><given-names>H</given-names></name><name><surname>Thombrayil</surname><given-names>A</given-names></name><name><surname>van</surname><given-names>ES</given-names></name><name><surname>Wibmer</surname><given-names>CK</given-names></name><name><surname>Durham</surname><given-names>NM</given-names></name><name><surname>Kelly</surname><given-names>EJ</given-names></name><name><surname>Villafana</surname><given-names>TL</given-names></name><name><surname>Gilbert</surname><given-names>S</given-names></name><name><surname>Pollard</surname><given-names>AJ</given-names></name><name><surname>de</surname><given-names>OT</given-names></name><name><surname>Moore</surname><given-names>PL</given-names></name><name><surname>Sigal</surname><given-names>A</given-names></name><name><surname>Izu</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Safety and Efficacy of the Chadox1 NCOV-19 (AZD1222) Covid-19 Vaccine against the b.1.351 Variant in South Africa</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2021.02.10.21251247</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahase</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Covid-19: Where are we on vaccines and variants</article-title><source>BMJ</source><volume>372</volume><elocation-id>n597</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.n597</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myszka</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors</article-title><source>Current Opinion in Biotechnology</source><volume>8</volume><fpage>50</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/s0958-1669(97)80157-7</pub-id><pub-id pub-id-type="pmid">9013659</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myszka</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Improving biosensor analysis</article-title><source>Journal of Molecular Recognition</source><volume>12</volume><fpage>279</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1099-1352(199909/10)12:5&lt;279::AID-JMR473&gt;3.0.CO;2-3</pub-id><pub-id pub-id-type="pmid">10556875</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Greenblatt</surname><given-names>DM</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><name><surname>Ferrin</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>UCSF Chimera--a visualization system for exploratory research and analysis</article-title><source>Journal of Computational Chemistry</source><volume>25</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rambaut</surname><given-names>A</given-names></name><name><surname>Holmes</surname><given-names>EC</given-names></name><name><surname>O’Toole</surname><given-names>Á</given-names></name><name><surname>Hill</surname><given-names>V</given-names></name><name><surname>McCrone</surname><given-names>JT</given-names></name><name><surname>Ruis</surname><given-names>C</given-names></name><name><surname>du Plessis</surname><given-names>L</given-names></name><name><surname>Pybus</surname><given-names>OG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A dynamic nomenclature proposal for sars-cov-2 lineages to assist genomic epidemiology</article-title><source>Nature Microbiology</source><volume>5</volume><fpage>1403</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0770-5</pub-id><pub-id pub-id-type="pmid">32669681</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>D</given-names></name><name><surname>Shaw</surname><given-names>LP</given-names></name><name><surname>Lanfear</surname><given-names>R</given-names></name><name><surname>Acman</surname><given-names>M</given-names></name><name><surname>Owen</surname><given-names>CJ</given-names></name><name><surname>Tan</surname><given-names>CC</given-names></name><name><surname>van</surname><given-names>DL</given-names></name><name><surname>Balloux</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A Phylogeny-Based Metric for Estimating Changes in Transmissibility from Recurrent Mutations in SARS-COV-2</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.05.06.442903</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>TF</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Beutler</surname><given-names>N</given-names></name><name><surname>Burns</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>W-T</given-names></name><name><surname>Limbo</surname><given-names>O</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Woehl</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Abbott</surname><given-names>RK</given-names></name><name><surname>Callaghan</surname><given-names>S</given-names></name><name><surname>Garcia</surname><given-names>E</given-names></name><name><surname>Hurtado</surname><given-names>J</given-names></name><name><surname>Parren</surname><given-names>M</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Ramirez</surname><given-names>S</given-names></name><name><surname>Ricketts</surname><given-names>J</given-names></name><name><surname>Ricciardi</surname><given-names>MJ</given-names></name><name><surname>Rawlings</surname><given-names>SA</given-names></name><name><surname>Wu</surname><given-names>NC</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Nemazee</surname><given-names>D</given-names></name><name><surname>Teijaro</surname><given-names>JR</given-names></name><name><surname>Voss</surname><given-names>JE</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Andrabi</surname><given-names>R</given-names></name><name><surname>Briney</surname><given-names>B</given-names></name><name><surname>Landais</surname><given-names>E</given-names></name><name><surname>Sok</surname><given-names>D</given-names></name><name><surname>Jardine</surname><given-names>JG</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Isolation of potent SARS-COV-2 neutralizing antibodies and protection from disease in a small animal model</article-title><source>Science</source><volume>369</volume><fpage>956</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1126/science.abc7520</pub-id><pub-id pub-id-type="pmid">32540903</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabino</surname><given-names>EC</given-names></name><name><surname>Buss</surname><given-names>LF</given-names></name><name><surname>Carvalho</surname><given-names>MPS</given-names></name><name><surname>Prete</surname><given-names>CA</given-names><suffix>Jr</suffix></name><name><surname>Crispim</surname><given-names>MAE</given-names></name><name><surname>Fraiji</surname><given-names>NA</given-names></name><name><surname>Pereira</surname><given-names>RHM</given-names></name><name><surname>Parag</surname><given-names>KV</given-names></name><name><surname>da Silva Peixoto</surname><given-names>P</given-names></name><name><surname>Kraemer</surname><given-names>MUG</given-names></name><name><surname>Oikawa</surname><given-names>MK</given-names></name><name><surname>Salomon</surname><given-names>T</given-names></name><name><surname>Cucunuba</surname><given-names>ZM</given-names></name><name><surname>Castro</surname><given-names>MC</given-names></name><name><surname>de Souza Santos</surname><given-names>AA</given-names></name><name><surname>Nascimento</surname><given-names>VH</given-names></name><name><surname>Pereira</surname><given-names>HS</given-names></name><name><surname>Ferguson</surname><given-names>NM</given-names></name><name><surname>Pybus</surname><given-names>OG</given-names></name><name><surname>Kucharski</surname><given-names>A</given-names></name><name><surname>Busch</surname><given-names>MP</given-names></name><name><surname>Dye</surname><given-names>C</given-names></name><name><surname>Faria</surname><given-names>NR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence</article-title><source>Lancet</source><volume>397</volume><fpage>452</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(21)00183-5</pub-id><pub-id pub-id-type="pmid">33515491</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sagulenko</surname><given-names>P</given-names></name><name><surname>Puller</surname><given-names>V</given-names></name><name><surname>Neher</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Treetime: Maximum-likelihood phylodynamic analysis</article-title><source>Virus Evolution</source><volume>4</volume><elocation-id>vex042</elocation-id><pub-id pub-id-type="doi">10.1093/ve/vex042</pub-id><pub-id pub-id-type="pmid">29340210</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="web"><person-group person-group-type="author"><collab>SARS-CoV-2 Variants of concern and variants under investigation - GOV.UK</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Variants of concern or under investigation: Data up to 19 May 2021</article-title><ext-link ext-link-type="uri" xlink:href="https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-cases-data">https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-cases-data</ext-link><date-in-citation iso-8601-date="2021-05-22">May 22, 2021</date-in-citation></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreiber</surname><given-names>G</given-names></name><name><surname>Fersht</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Rapid, electrostatically assisted Association of proteins</article-title><source>Nature Structural Biology</source><volume>3</volume><fpage>427</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1038/nsb0596-427</pub-id><pub-id pub-id-type="pmid">8612072</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>K</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Aihara</surname><given-names>H</given-names></name><name><surname>Geng</surname><given-names>Q</given-names></name><name><surname>Auerbach</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis of receptor recognition by SARS-COV-2</article-title><source>Nature</source><volume>581</volume><fpage>221</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2179-y</pub-id><pub-id pub-id-type="pmid">32225175</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>Y</given-names></name><name><surname>McCauley</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>GISAID: Global initiative on sharing all influenza data - from vision to reality</article-title><source>Euro Surveillance</source><volume>22</volume><elocation-id>30494</elocation-id><pub-id pub-id-type="doi">10.2807/1560-7917.es.2017.22.13.30494</pub-id><pub-id pub-id-type="pmid">28382917</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starr</surname><given-names>TN</given-names></name><name><surname>Greaney</surname><given-names>AJ</given-names></name><name><surname>Hilton</surname><given-names>SK</given-names></name><name><surname>Ellis</surname><given-names>D</given-names></name><name><surname>Crawford</surname><given-names>KHD</given-names></name><name><surname>Dingens</surname><given-names>AS</given-names></name><name><surname>Navarro</surname><given-names>MJ</given-names></name><name><surname>Bowen</surname><given-names>JE</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>King</surname><given-names>NP</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Deep mutational scanning of SARS-COV-2 receptor binding domain reveals constraints on folding and ace2 binding</article-title><source>Cell</source><volume>182</volume><fpage>1295</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.08.012</pub-id><pub-id pub-id-type="pmid">32841599</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Supasa</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Dejnirattisai</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Mentzer</surname><given-names>AJ</given-names></name><name><surname>Ginn</surname><given-names>HM</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Duyvesteyn</surname><given-names>HME</given-names></name><name><surname>Nutalai</surname><given-names>R</given-names></name><name><surname>Tuekprakhon</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Paesen</surname><given-names>GC</given-names></name><name><surname>Slon-Campos</surname><given-names>J</given-names></name><name><surname>López-Camacho</surname><given-names>C</given-names></name><name><surname>Hallis</surname><given-names>B</given-names></name><name><surname>Coombes</surname><given-names>N</given-names></name><name><surname>Bewley</surname><given-names>KR</given-names></name><name><surname>Charlton</surname><given-names>S</given-names></name><name><surname>Walter</surname><given-names>TS</given-names></name><name><surname>Barnes</surname><given-names>E</given-names></name><name><surname>Dunachie</surname><given-names>SJ</given-names></name><name><surname>Skelly</surname><given-names>D</given-names></name><name><surname>Lumley</surname><given-names>SF</given-names></name><name><surname>Baker</surname><given-names>N</given-names></name><name><surname>Shaik</surname><given-names>I</given-names></name><name><surname>Humphries</surname><given-names>HE</given-names></name><name><surname>Godwin</surname><given-names>K</given-names></name><name><surname>Gent</surname><given-names>N</given-names></name><name><surname>Sienkiewicz</surname><given-names>A</given-names></name><name><surname>Dold</surname><given-names>C</given-names></name><name><surname>Levin</surname><given-names>R</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><name><surname>Pollard</surname><given-names>AJ</given-names></name><name><surname>Knight</surname><given-names>JC</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Crook</surname><given-names>D</given-names></name><name><surname>Lambe</surname><given-names>T</given-names></name><name><surname>Clutterbuck</surname><given-names>E</given-names></name><name><surname>Bibi</surname><given-names>S</given-names></name><name><surname>Flaxman</surname><given-names>A</given-names></name><name><surname>Bittaye</surname><given-names>M</given-names></name><name><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name><name><surname>Gilbert</surname><given-names>S</given-names></name><name><surname>Hall</surname><given-names>DR</given-names></name><name><surname>Williams</surname><given-names>MA</given-names></name><name><surname>Paterson</surname><given-names>NG</given-names></name><name><surname>James</surname><given-names>W</given-names></name><name><surname>Carroll</surname><given-names>MW</given-names></name><name><surname>Fry</surname><given-names>EE</given-names></name><name><surname>Mongkolsapaya</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Stuart</surname><given-names>DI</given-names></name><name><surname>Screaton</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Reduced neutralization of SARS-COV-2 b.1.1.7 variant by convalescent and vaccine Sera</article-title><source>Cell</source><volume>184</volume><fpage>2201</fpage><lpage>2211</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.02.033</pub-id><pub-id pub-id-type="pmid">33743891</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tegally</surname><given-names>H</given-names></name><name><surname>Wilkinson</surname><given-names>E</given-names></name><name><surname>Giovanetti</surname><given-names>M</given-names></name><name><surname>Iranzadeh</surname><given-names>A</given-names></name><name><surname>Fonseca</surname><given-names>V</given-names></name><name><surname>Giandhari</surname><given-names>J</given-names></name><name><surname>Doolabh</surname><given-names>D</given-names></name><name><surname>Pillay</surname><given-names>S</given-names></name><name><surname>San</surname><given-names>EJ</given-names></name><name><surname>Msomi</surname><given-names>N</given-names></name><name><surname>Mlisana</surname><given-names>K</given-names></name><name><surname>von</surname><given-names>GA</given-names></name><name><surname>Walaza</surname><given-names>S</given-names></name><name><surname>Allam</surname><given-names>M</given-names></name><name><surname>Ismail</surname><given-names>A</given-names></name><name><surname>Mohale</surname><given-names>T</given-names></name><name><surname>Glass</surname><given-names>AJ</given-names></name><name><surname>Engelbrecht</surname><given-names>S</given-names></name><name><surname>Zyl</surname><given-names>GV</given-names></name><name><surname>Preiser</surname><given-names>W</given-names></name><name><surname>Petruccione</surname><given-names>F</given-names></name><name><surname>Sigal</surname><given-names>A</given-names></name><name><surname>Hardie</surname><given-names>D</given-names></name><name><surname>Marais</surname><given-names>G</given-names></name><name><surname>Hsiao</surname><given-names>M</given-names></name><name><surname>Korsman</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>MA</given-names></name><name><surname>Tyers</surname><given-names>L</given-names></name><name><surname>Mudau</surname><given-names>I</given-names></name><name><surname>York</surname><given-names>D</given-names></name><name><surname>Maslo</surname><given-names>C</given-names></name><name><surname>Goedhals</surname><given-names>D</given-names></name><name><surname>Abrahams</surname><given-names>S</given-names></name><name><surname>Laguda-Akingba</surname><given-names>O</given-names></name><name><surname>Alisoltani-Dehkordi</surname><given-names>A</given-names></name><name><surname>Godzik</surname><given-names>A</given-names></name><name><surname>Wibmer</surname><given-names>CK</given-names></name><name><surname>Sewell</surname><given-names>BT</given-names></name><name><surname>Lourenço</surname><given-names>J</given-names></name><name><surname>Alcantara</surname><given-names>LCJ</given-names></name><name><surname>Pond</surname><given-names>SLK</given-names></name><name><surname>Weaver</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>D</given-names></name><name><surname>Lessells</surname><given-names>RJ</given-names></name><name><surname>Bhiman</surname><given-names>JN</given-names></name><name><surname>Williamson</surname><given-names>C</given-names></name><name><surname>de</surname><given-names>OT</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Emergence of a SARS-COV-2 variant of concern with mutations in spike glycoprotein</article-title><source>Nature</source><volume>592</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03402-9</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Merwe</surname><given-names>PA</given-names></name><name><surname>Barclay</surname><given-names>AN</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Analysis of cell-adhesion molecule interactions using surface plasmon resonance</article-title><source>Current Opinion in Immunology</source><volume>8</volume><fpage>257</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/s0952-7915(96)80065-3</pub-id><pub-id pub-id-type="pmid">8725949</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Volz</surname><given-names>E</given-names></name><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Chand</surname><given-names>M</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Transmission of SARS-COV-2 Lineage b.1.1.7 in England: Insights from Linking Epidemiological and Genetic Data</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.12.30.20249034</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volz</surname><given-names>E</given-names></name><name><surname>Hill</surname><given-names>V</given-names></name><name><surname>McCrone</surname><given-names>JT</given-names></name><name><surname>Price</surname><given-names>A</given-names></name><name><surname>Jorgensen</surname><given-names>D</given-names></name><name><surname>O’Toole</surname><given-names>Á</given-names></name><name><surname>Southgate</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Jackson</surname><given-names>B</given-names></name><name><surname>Nascimento</surname><given-names>FF</given-names></name><name><surname>Rey</surname><given-names>SM</given-names></name><name><surname>Nicholls</surname><given-names>SM</given-names></name><name><surname>Colquhoun</surname><given-names>RM</given-names></name><name><surname>da Silva Filipe</surname><given-names>A</given-names></name><name><surname>Shepherd</surname><given-names>J</given-names></name><name><surname>Pascall</surname><given-names>DJ</given-names></name><name><surname>Shah</surname><given-names>R</given-names></name><name><surname>Jesudason</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Jarrett</surname><given-names>R</given-names></name><name><surname>Pacchiarini</surname><given-names>N</given-names></name><name><surname>Bull</surname><given-names>M</given-names></name><name><surname>Geidelberg</surname><given-names>L</given-names></name><name><surname>Siveroni</surname><given-names>I</given-names></name><collab>COG-UK Consortium</collab><name><surname>Goodfellow</surname><given-names>I</given-names></name><name><surname>Loman</surname><given-names>NJ</given-names></name><name><surname>Pybus</surname><given-names>OG</given-names></name><name><surname>Robertson</surname><given-names>DL</given-names></name><name><surname>Thomson</surname><given-names>EC</given-names></name><name><surname>Rambaut</surname><given-names>A</given-names></name><name><surname>Connor</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Evaluating the effects of SARS-COV-2 spike mutation D614G on transmissibility and pathogenicity</article-title><source>Cell</source><volume>184</volume><fpage>64</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.11.020</pub-id><pub-id pub-id-type="pmid">33275900</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>V’kovski</surname><given-names>P</given-names></name><name><surname>Kratzel</surname><given-names>A</given-names></name><name><surname>Steiner</surname><given-names>S</given-names></name><name><surname>Stalder</surname><given-names>H</given-names></name><name><surname>Thiel</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Coronavirus biology and replication: Implications for SARS-COV-2</article-title><source>Nature Reviews. Microbiology</source><volume>19</volume><fpage>155</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-00468-6</pub-id><pub-id pub-id-type="pmid">33116300</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Schmidt</surname><given-names>F</given-names></name><name><surname>Weisblum</surname><given-names>Y</given-names></name><name><surname>Muecksch</surname><given-names>F</given-names></name><name><surname>Barnes</surname><given-names>CO</given-names></name><name><surname>Finkin</surname><given-names>S</given-names></name><name><surname>Schaefer-Babajew</surname><given-names>D</given-names></name><name><surname>Cipolla</surname><given-names>M</given-names></name><name><surname>Gaebler</surname><given-names>C</given-names></name><name><surname>Lieberman</surname><given-names>JA</given-names></name><name><surname>Oliveira</surname><given-names>TY</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Abernathy</surname><given-names>ME</given-names></name><name><surname>Huey-Tubman</surname><given-names>KE</given-names></name><name><surname>Hurley</surname><given-names>A</given-names></name><name><surname>Turroja</surname><given-names>M</given-names></name><name><surname>West</surname><given-names>KA</given-names></name><name><surname>Gordon</surname><given-names>K</given-names></name><name><surname>Millard</surname><given-names>KG</given-names></name><name><surname>Ramos</surname><given-names>V</given-names></name><name><surname>Da Silva</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Colbert</surname><given-names>RA</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Dizon</surname><given-names>J</given-names></name><name><surname>Unson-O’Brien</surname><given-names>C</given-names></name><name><surname>Shimeliovich</surname><given-names>I</given-names></name><name><surname>Gazumyan</surname><given-names>A</given-names></name><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Casellas</surname><given-names>R</given-names></name><name><surname>Hatziioannou</surname><given-names>T</given-names></name><name><surname>Bieniasz</surname><given-names>PD</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>MRNA vaccine-elicited antibodies to SARS-COV-2 and circulating variants</article-title><source>Nature</source><volume>592</volume><fpage>616</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03324-6</pub-id><pub-id pub-id-type="pmid">33567448</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Washington</surname><given-names>NL</given-names></name><name><surname>Gangavarapu</surname><given-names>K</given-names></name><name><surname>Zeller</surname><given-names>M</given-names></name><name><surname>Bolze</surname><given-names>A</given-names></name><name><surname>Cirulli</surname><given-names>ET</given-names></name><name><surname>Schiabor Barrett</surname><given-names>KM</given-names></name><name><surname>Larsen</surname><given-names>BB</given-names></name><name><surname>Anderson</surname><given-names>C</given-names></name><name><surname>White</surname><given-names>S</given-names></name><name><surname>Cassens</surname><given-names>T</given-names></name><name><surname>Jacobs</surname><given-names>S</given-names></name><name><surname>Levan</surname><given-names>G</given-names></name><name><surname>Nguyen</surname><given-names>J</given-names></name><name><surname>Ramirez</surname><given-names>JM</given-names></name><name><surname>Rivera-Garcia</surname><given-names>C</given-names></name><name><surname>Sandoval</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wong</surname><given-names>D</given-names></name><name><surname>Spencer</surname><given-names>E</given-names></name><name><surname>Robles-Sikisaka</surname><given-names>R</given-names></name><name><surname>Kurzban</surname><given-names>E</given-names></name><name><surname>Hughes</surname><given-names>LD</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Servellita</surname><given-names>V</given-names></name><name><surname>Valentine</surname><given-names>H</given-names></name><name><surname>De Hoff</surname><given-names>P</given-names></name><name><surname>Seaver</surname><given-names>P</given-names></name><name><surname>Sathe</surname><given-names>S</given-names></name><name><surname>Gietzen</surname><given-names>K</given-names></name><name><surname>Sickler</surname><given-names>B</given-names></name><name><surname>Antico</surname><given-names>J</given-names></name><name><surname>Hoon</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Harding</surname><given-names>A</given-names></name><name><surname>Bakhtar</surname><given-names>O</given-names></name><name><surname>Basler</surname><given-names>T</given-names></name><name><surname>Austin</surname><given-names>B</given-names></name><name><surname>MacCannell</surname><given-names>D</given-names></name><name><surname>Isaksson</surname><given-names>M</given-names></name><name><surname>Febbo</surname><given-names>PG</given-names></name><name><surname>Becker</surname><given-names>D</given-names></name><name><surname>Laurent</surname><given-names>M</given-names></name><name><surname>McDonald</surname><given-names>E</given-names></name><name><surname>Yeo</surname><given-names>GW</given-names></name><name><surname>Knight</surname><given-names>R</given-names></name><name><surname>Laurent</surname><given-names>LC</given-names></name><name><surname>de Feo</surname><given-names>E</given-names></name><name><surname>Worobey</surname><given-names>M</given-names></name><name><surname>Chiu</surname><given-names>CY</given-names></name><name><surname>Suchard</surname><given-names>MA</given-names></name><name><surname>Lu</surname><given-names>JT</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Andersen</surname><given-names>KG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Emergence and rapid transmission of SARS-COV-2 b.1.1.7 in the United States</article-title><source>Cell</source><volume>184</volume><fpage>2587</fpage><lpage>2594</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.03.052</pub-id><pub-id pub-id-type="pmid">33861950</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Additivity of mutational effects in proteins</article-title><source>Biochemistry</source><volume>29</volume><fpage>8509</fpage><lpage>8517</lpage><pub-id pub-id-type="doi">10.1021/bi00489a001</pub-id><pub-id pub-id-type="pmid">2271534</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="web"><person-group person-group-type="author"><collab>WHO</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Coronavirus (COVID-19) dashboard</article-title><ext-link ext-link-type="uri" xlink:href="https://covid19.who.int/">https://covid19.who.int/</ext-link><date-in-citation iso-8601-date="2021-04-22">April 22, 2021</date-in-citation></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wölfel</surname><given-names>R</given-names></name><name><surname>Corman</surname><given-names>VM</given-names></name><name><surname>Guggemos</surname><given-names>W</given-names></name><name><surname>Seilmaier</surname><given-names>M</given-names></name><name><surname>Zange</surname><given-names>S</given-names></name><name><surname>Müller</surname><given-names>MA</given-names></name><name><surname>Niemeyer</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>TC</given-names></name><name><surname>Vollmar</surname><given-names>P</given-names></name><name><surname>Rothe</surname><given-names>C</given-names></name><name><surname>Hoelscher</surname><given-names>M</given-names></name><name><surname>Bleicker</surname><given-names>T</given-names></name><name><surname>Brünink</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>J</given-names></name><name><surname>Ehmann</surname><given-names>R</given-names></name><name><surname>Zwirglmaier</surname><given-names>K</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Wendtner</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Virological assessment of hospitalized patients with covid-2019</article-title><source>Nature</source><volume>581</volume><fpage>465</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2196-x</pub-id><pub-id pub-id-type="pmid">32235945</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Goldsmith</surname><given-names>JA</given-names></name><name><surname>Hsieh</surname><given-names>CL</given-names></name><name><surname>Abiona</surname><given-names>O</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cryo-em structure of the 2019-ncov spike in the prefusion conformation</article-title><source>Science</source><volume>367</volume><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis for the recognition of SARS-COV-2 by full-length human ace2</article-title><source>Science</source><volume>367</volume><fpage>1444</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1126/science.abb2762</pub-id><pub-id pub-id-type="pmid">32132184</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Zahradník</surname><given-names>J</given-names></name><name><surname>Marciano</surname><given-names>S</given-names></name><name><surname>Shemesh</surname><given-names>M</given-names></name><name><surname>Zoler</surname><given-names>E</given-names></name><name><surname>Chiaravalli</surname><given-names>J</given-names></name><name><surname>Meyer</surname><given-names>B</given-names></name><name><surname>Rudich</surname><given-names>Y</given-names></name><name><surname>Dym</surname><given-names>O</given-names></name><name><surname>Elad</surname><given-names>N</given-names></name><name><surname>Schreiber</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-COV-2 RBD in Vitro Evolution Follows Contagious Mutation Spread, yet Generates an Able Infection Inhibitor</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.01.06.425392</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Jackson</surname><given-names>CB</given-names></name><name><surname>Mou</surname><given-names>H</given-names></name><name><surname>Ojha</surname><given-names>A</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Quinlan</surname><given-names>BD</given-names></name><name><surname>Rangarajan</surname><given-names>ES</given-names></name><name><surname>Pan</surname><given-names>A</given-names></name><name><surname>Vanderheiden</surname><given-names>A</given-names></name><name><surname>Suthar</surname><given-names>MS</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Izard</surname><given-names>T</given-names></name><name><surname>Rader</surname><given-names>C</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name><name><surname>Choe</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-COV-2 spike-protein D614G mutation increases virion spike density and infectivity</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>6013</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-19808-4</pub-id><pub-id pub-id-type="pmid">33243994</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Sterling</surname><given-names>SM</given-names></name><name><surname>Walsh</surname><given-names>RM</given-names></name><name><surname>Rits-Volloch</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Woosley</surname><given-names>AN</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Sliz</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structural impact on SARS-COV-2 spike protein by d614g substitution</article-title><source>Science</source><volume>372</volume><fpage>525</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1126/science.abf2303</pub-id><pub-id pub-id-type="pmid">33727252</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Dcosta</surname><given-names>BM</given-names></name><name><surname>Samanovic</surname><given-names>MI</given-names></name><name><surname>Mulligan</surname><given-names>MJ</given-names></name><name><surname>Landau</surname><given-names>NR</given-names></name><name><surname>Tada</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>B.1.526 Sars-Cov-2 Variants Identified in New York City Are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.03.24.436620</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Dejnirattisai</surname><given-names>W</given-names></name><name><surname>Supasa</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Mentzer</surname><given-names>AJ</given-names></name><name><surname>Ginn</surname><given-names>HM</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Duyvesteyn</surname><given-names>HME</given-names></name><name><surname>Tuekprakhon</surname><given-names>A</given-names></name><name><surname>Nutalai</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Paesen</surname><given-names>GC</given-names></name><name><surname>Lopez-Camacho</surname><given-names>C</given-names></name><name><surname>Slon-Campos</surname><given-names>J</given-names></name><name><surname>Hallis</surname><given-names>B</given-names></name><name><surname>Coombes</surname><given-names>N</given-names></name><name><surname>Bewley</surname><given-names>K</given-names></name><name><surname>Charlton</surname><given-names>S</given-names></name><name><surname>Walter</surname><given-names>TS</given-names></name><name><surname>Skelly</surname><given-names>D</given-names></name><name><surname>Lumley</surname><given-names>SF</given-names></name><name><surname>Dold</surname><given-names>C</given-names></name><name><surname>Levin</surname><given-names>R</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><name><surname>Pollard</surname><given-names>AJ</given-names></name><name><surname>Knight</surname><given-names>JC</given-names></name><name><surname>Crook</surname><given-names>D</given-names></name><name><surname>Lambe</surname><given-names>T</given-names></name><name><surname>Clutterbuck</surname><given-names>E</given-names></name><name><surname>Bibi</surname><given-names>S</given-names></name><name><surname>Flaxman</surname><given-names>A</given-names></name><name><surname>Bittaye</surname><given-names>M</given-names></name><name><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name><name><surname>Gilbert</surname><given-names>S</given-names></name><name><surname>James</surname><given-names>W</given-names></name><name><surname>Carroll</surname><given-names>MW</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Barnes</surname><given-names>E</given-names></name><name><surname>Dunachie</surname><given-names>SJ</given-names></name><name><surname>Fry</surname><given-names>EE</given-names></name><name><surname>Mongkolsapaya</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Stuart</surname><given-names>DI</given-names></name><name><surname>Screaton</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera</article-title><source>Cell</source><volume>184</volume><fpage>2348</fpage><lpage>2361</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.02.037</pub-id><pub-id pub-id-type="pmid">33730597</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.70658.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Fouchier</surname><given-names>Ron AM</given-names></name><role>Reviewing Editor</role><aff><institution>Erasmus Medical Center</institution><country>Netherlands</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Fouchier</surname><given-names>Ron AM</given-names></name><role>Reviewer</role><aff><institution>Erasmus Medical Center</institution><country>Netherlands</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.05.18.444646">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.05.18.444646v2">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This manuscript is of interest to infectious disease specialists, biochemists and biophysicists working on SARS-CoV-2. It provides detailed and rigorous affinity and kinetics analyses of the effect of several biologically relevant amino acid substitutions in the SARS-CoV-2 receptor binding domain and ACE2 as measured by surface plasmon resonance with recombinant proteins. Although the study is limited to a binding analysis of monomeric protein domains, the data may contribute to understand the rapid emergence of SARS-CoV-2 variants with substitutions in the spike protein.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Effects of common mutations in the SARS-CoV-2 Spike RBD domain and its ligand the human ACE2 receptor on binding affinity and kinetics&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Ron AM Fouchier as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Jos van der Meer as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>No new experiments are required but numerous suggestions have been made by the 3 reviewers to correct or clarify the text.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Several countries have requested to not use country names in virus lineage descriptions, to avoid stigmatization. I would suggest to (maximally) once in the manuscript mention for each lineage where it was first detected, and afterwards refrain from using country names and country codes. In many tables and figures and legends and texts, these names recur (e.g. table 2, Figure S2 and elsewhere).</p><p>Line 20. SARS-CoV-2 is not the second coronavirus that can induce a severe acute respiratory syndrome; all human coronaviruses can do that, and so can SARS-CoV and MERS-CoV.</p><p>Line 22. This is a matter of debate. I guess the authors only take infectious disease pandemics into account and do not consider the HIV pandemic to have unfolded in the past 100 years?</p><p>Line 61 and elsewhere. The authors mention &quot;physiological temperature&quot;. It would be useful throughout the text to add the exact temperature used (37C) in statements like this. The temperature in the human airways is not the same everywhere (less than 37C in the upper airways). It is better to be exact.</p><p>On several occasions in the manuscript, the authors use &quot;transmissivity&quot; where they probably mean &quot;transmissibility&quot;.</p><p>I prefer to reserve the term &quot;mutations&quot; in biology to changes of the DNA/RNA, that may or may lead to &quot;substitutions&quot; in proteins. Personally, I dislike the term &quot;mutations&quot; when speaking of proteins and rather see amino acid &quot;substitutions&quot; or &quot;changes&quot;.</p><p>L240. RBD domain. Delete &quot;domain&quot;.</p><p>L232-235. While increased affinity may increase infection efficiency, it may have the downside of reducing virus release (and potentially transmission)?</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Additional data on the effects of variant mutations on ACE2 or cell binding using whole spikes or (pseudotyped) virus particles would add novelty.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>(1) Did the authors use reducing or non-reducing SDS-PAGE in Figure S2 that could address whether disulfide-linked dimers are present?</p><p>(2) The &quot;D&quot; of &quot;RBD&quot; in the title already includes the meaning of &quot;domain&quot;. Can the &quot;Spike RBD domain&quot; be replaced by &quot;Spike receptor-binding domain&quot; or simply &quot;Spike RBD&quot;?</p><p>(3) Page 5, line 82. Please change &quot;20A/S:4.4K&quot; to &quot;20A/S.484K&quot;</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.70658.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>No new experiments are required but numerous suggestions have been made by the 3 reviewers to correct or clarify the text.</p><p>Reviewer #1 (Recommendations for the authors):</p><p>Several countries have requested to not use country names in virus lineage descriptions, to avoid stigmatization. I would suggest to (maximally) once in the manuscript mention for each lineage where it was first detected, and afterwards refrain from using country names and country codes. In many tables and figures and legends and texts, these names recur (e.g. table 2, Figure S2 and elsewhere).</p></disp-quote><p>We have made the requested changes and added the new WHO variant nomenclature to the text, tables, figures, and figure legends.</p><disp-quote content-type="editor-comment"><p>Line 20. SARS-CoV-2 is not the second coronavirus that can induce a severe acute respiratory syndrome; all human coronaviruses can do that, and so can SARS-CoV and MERS-CoV.</p></disp-quote><p>We have corrected this.</p><disp-quote content-type="editor-comment"><p>Line 22. This is a matter of debate. I guess the authors only take infectious disease pandemics into account and do not consider the HIV pandemic to have unfolded in the past 100 years?</p></disp-quote><p>We appreciate that some might consider the HIV pandemic to have been worse that SARS-CoV-2 pandemic and have adjusted the text accordingly. We have also clarified that we are referring to infectious disease pandemics.</p><disp-quote content-type="editor-comment"><p>Line 61 and elsewhere. The authors mention &quot;physiological temperature&quot;. It would be useful throughout the text to add the exact temperature used (37C) in statements like this. The temperature in the human airways is not the same everywhere (less than 37C in the upper airways). It is better to be exact.</p></disp-quote><p>We accept this and have amended the text.</p><disp-quote content-type="editor-comment"><p>On several occasions in the manuscript, the authors use &quot;transmissivity&quot; where they probably mean &quot;transmissibility&quot;.</p></disp-quote><p>We have corrected this.</p><disp-quote content-type="editor-comment"><p>I prefer to reserve the term &quot;mutations&quot; in biology to changes of the DNA/RNA, that may or may lead to &quot;substitutions&quot; in proteins. Personally, I dislike the term &quot;mutations&quot; when speaking of proteins and rather see amino acid &quot;substitutions&quot; or &quot;changes&quot;.</p></disp-quote><p>While we appreciate this point, we think is reasonable, in the interest of brevity, to use ‘mutations’ as shorthand for the phrase ‘mutations which results in the amino acid substitutions’. We think its meaning is clear.</p><disp-quote content-type="editor-comment"><p>L240. RBD domain. Delete &quot;domain&quot;.</p></disp-quote><p>We have corrected this here and throughout the text, including in the title.</p><disp-quote content-type="editor-comment"><p>L232-235. While increased affinity may increase infection efficiency, it may have the downside of reducing virus release (and potentially transmission)?</p></disp-quote><p>While we agree that increased affinity could <italic>decrease</italic> transmission, e.g. via reducing viral release, this point is not obviously relevant in this study which is focused on variants whose spread suggests <italic>increased</italic> transmission.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>(1) Did the authors use reducing or non-reducing SDS-PAGE in Figure S2 that could address whether disulfide-linked dimers are present?</p></disp-quote><p>We used reducing SDS PAGE gels. We have added this to the Materials and methods and Figure 2—figure supplement 1 legend (previously Figure S2).</p><disp-quote content-type="editor-comment"><p>(2) The &quot;D&quot; of &quot;RBD&quot; in the title already includes the meaning of &quot;domain&quot;. Can the &quot;Spike RBD domain&quot; be replaced by &quot;Spike receptor-binding domain&quot; or simply &quot;Spike RBD&quot;?</p></disp-quote><p>We have corrected this.</p><disp-quote content-type="editor-comment"><p>(3) Page 5, line 82. Please change &quot;20A/S:4.4K&quot; to &quot;20A/S.484K&quot;</p></disp-quote><p>We have corrected this.</p></body></sub-article></article>